0001104659-22-068019.txt : 20220603 0001104659-22-068019.hdr.sgml : 20220603 20220603145931 ACCESSION NUMBER: 0001104659-22-068019 CONFORMED SUBMISSION TYPE: N-CSRS PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220603 DATE AS OF CHANGE: 20220603 EFFECTIVENESS DATE: 20220603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEKLA HEALTHCARE INVESTORS CENTRAL INDEX KEY: 0000805267 IRS NUMBER: 046564285 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: N-CSRS SEC ACT: 1940 Act SEC FILE NUMBER: 811-04889 FILM NUMBER: 22994028 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS DATE OF NAME CHANGE: 19920703 N-CSRS 1 tm228075d1_ncsrs.htm N-CSRS

 

    OMB APPROVAL
    OMB Number: 3235-0570
    Expires: July 31, 2022
  UNITED STATES Estimated average burden hours per response. . . . . . . . . . . . . . .20.6
  SECURITIES AND EXCHANGE COMMISSION  
  Washington, D.C. 20549  

 

FORM N-CSR

 

CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES

 

Investment Company Act file number 811-04889
 
Tekla Healthcare Investors
(Exact name of registrant as specified in charter)
 
100 Federal Street, 19th Floor, Boston, MA   02110
(Address of principal executive offices)   (Zip code)
 
 
(Name and address of agent for service)
 
Registrant’s telephone number, including area code: 617-772-8500  
 
Date of fiscal year end: September 30  
 
Date of reporting period: October 1, 2021 to March 31, 2022  
                   

 

 

 

ITEM 1. REPORTS TO STOCKHOLDERS.

 

 

  

TEKLA HEALTHCARE INVESTORS

Semiannual Report

March 31, 2022

TEKLA HEALTHCARE INVESTORS

Distribution policy: The Fund has implemented a managed distribution policy (the Policy) that provides for quarterly distributions at a rate set by the Board of Trustees. Under the current Policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Policy would result in a return of capital to shareholders, if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."

The amounts and sources of distributions reported in the Fund's notices pursuant to Section 19(a) of the Investment Company Act of 1940 are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that tells you how to report distributions for federal income tax purposes.

You should not draw any conclusions about the Fund's investment performance from the amount of distributions pursuant to the Policy or from the terms of the Policy. The Policy has been established by the Trustees and may be changed or terminated by them without shareholder approval. The Trustees regularly review the Policy and the frequency and rate of distributions considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions. The suspension or termination of the Policy could have the effect of creating a trading discount or widening an existing trading discount. At this time there are no reasonably foreseeable circumstances that might cause the Trustees to terminate the Policy.

Consider these risks before investing: As with any investment company that invests in equity securities, the Fund is subject to market risk—the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market generally and market sectors in particular. You could lose money over short or long periods of time. Political and economic news can influence marketwide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares. Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity securities of healthcare companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.

TEKLA HEALTHCARE INVESTORS

Dear Shareholders,

Many of us have spent the last two years constrained in how we live our lives. More than eighty million Americans have been sick while nearly a million have lost their lives to COVID-19. An enormous number of Americans of all ages have been damaged financially, socially, educationally and/or medically. However, as of early May 2022, we appear to be approaching a time when we can resume what we were doing pre-COVID-19. This should allow us to address much of what has been lost or delayed by the pandemic. This is the good news.

The bad news is that things are not perfect from an economic or markets point of view. The broad market was down as COVID-19 came to the fore and then rose dramatically through much of 2020 and 2021 as the government did all it could to stimulate the economy while keeping rates low. However, there is a limit to how long this approach can continue and still be effective. The broad market has been weak so far in 2022, particularly lately. Based on data to date, it looks that we are in for a protracted period of high inflation. This will cause the Federal Reserve to continue to increase rates, perhaps significantly. GDP has already slowed; it seems likely that GDP will be impaired further with a real possibility that the U.S. experiences a recession. These prospects will almost certainly have a continued negative impact on the stock market. April 2022 was not a good month for the broad stock market. It remains to be seen where the market goes from here.

The macroeconomic impact on the healthcare sector market has varied by subsector. Large cap, profitable healthcare companies in the pharmaceutical and biotech subsectors, for example, have traditionally been seen as defensive and have fared relatively well of late. However, smaller cap not-yet profitable healthcare companies, particularly in the biotech sector, have not done well. In fact, this group peaked in early 2021 and has been in decline since. For reference, we note that in 2022 through April 30, the broad S&P 500® Index* (SPX) is down almost 13%. In the same timeframe, large healthcare companies in the broader S&P Composite 1500® Health Care Index* (S15HLTH) are down about 8% while more volatile small- and mid- cap (SMID) biotech companies, as evidenced by the SPDR® S&P® Biotech ETF* (XBI), which are expected to be weak in rising rate environments, are down 34%.


1

Performance Year to Date Ending April 30, 2022

In addition to being affected by rising rates, the SMID biotech sector is also being challenged by oversupply. In the euphoria of the COVID-19 era market run, over 300 biotech companies went public. This number might have been accommodated in the frenzied market action of 2016 to 2020 but will take some time to digest now that demand for such companies has waned a bit.

We remain bullish about healthcare overall and continue to think that it offers a unique opportunity to invest in most or all macro environments. That is, when the macro environment is strong, innovative subsectors such as biotech can provide the opportunity for upside participation while, when things are more challenging, pharma and managed care provide an opportunity to be a bit more defensive. In recent times, we have generally followed this approach, decreasing our allocation to smaller, more volatile names while increasing allocation to larger more defensive names (as well as incrementally increasing our use of cash) when we expect that the macroeconomic environment will be weak.

While we can adjust our investment approach consistent with short-term market dynamics, we remain more focused on the intermediate- and long-term trends. We remain bullish over the long-term. As noted, we believe there most often is a relatively attractive subsector within healthcare. More importantly, we think the sector offers an attractive long-term investment profile. Gross healthcare spending has increased inexorably for many decades. Moreover, demographics favor the sector as the U.S. population is aging and people spend more on healthcare as they get older. While innovation and prospective growth may be out of favor at the moment, these traits, as evidenced by the biotech sector, have consistently been the basis for solid returns when judiciously acquired and held. In our view, there are few sub-sectors that offer more attractive long-term prospects than healthcare in general or the biotech subsector. We think the recent weakness in the SMID biotech sector described above will


2

ultimately provide an attractive investing opportunity for discerning and informed investors, including your Tekla Fund.

Be well,

     

 

Daniel R. Omstead
President and Portfolio Manager


3

Fund Essentials

Objective of the Fund

The Fund's investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. In addition, the Fund seeks to provide regular distribution of realized capital gains.

Description of the Fund

Tekla Healthcare Investors (HQH) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. HQH primarily invests in healthcare industries and will emphasize both large established companies and smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies.

Investment Philosophy

Tekla Capital Management LLC, the Investment Adviser to the Fund, believes that:

•  Aging demographics and adoption of new medical products and services can provide long-term tailwinds for healthcare companies

•  Late stage biotechnology and pharma product pipeline could lead to significant increases in biotechnology sales

•  Robust M&A activity in healthcare may create additional investment opportunities

Fund Overview and Characteristics as of 3/31/22

Market Price1

   $20.77  

NAV2

   $21.94  

Premium/(Discount)

   -5.33%  

Average 30 Day Volume

   127,624  

Net Assets

   $1,016,941,189  

Ticker

  

HQH

  

NAV Ticker

  

XHQHX

  
Commencement of
Operations Date		  

4/22/87

  
Fiscal Year to Date
Distributions
per Share		   $0.99  

1 The closing price at which the Fund's shares were traded on the exchange.

2 Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.

Holdings of the Fund (Data is based on net assets)

Asset Allocation as of 3/31/22

Sector Diversification as of 3/31/22

This data is subject to change on a daily basis.


4

Largest Holdings By Issuer

(Excludes Short-Term Investments)

As of March 31, 2022
(Unaudited)

Issuer – Sector   % of Net
Assets		  
Amgen, Inc. – Biotechnology    

7.7

%

  
Regeneron Pharmaceuticals, Inc. – Biotechnology    

5.6

%

  
Vertex Pharmaceuticals, Inc. – Biotechnology    

5.1

%

  
Gilead Sciences, Inc. – Biotechnology    

5.0

%

  
Horizon Therapeutics plc – Pharmaceuticals    

4.8

%

  
Illumina, Inc. – Life Sciences Tools & Services    

4.4

%

  
Seagen, Inc. – Biotechnology    

2.4

%

  
Moderna, Inc. – Biotechnology    

2.3

%

  
AstraZeneca plc – Pharmaceuticals    

2.3

%

  
UnitedHealth Group, Inc. – Health Care Providers & Services    

2.2

%

  
Stryker Corp. – Health Care Equipment & Supplies    

2.0

%

  
AbbVie, Inc. – Biotechnology    

1.8

%

  
Alnylam Pharmaceuticals, Inc. – Biotechnology    

1.5

%

  
McKesson Corp. – Pharmaceuticals    

1.4

%

  
Syneos Health, Inc. – Healthcare Services    

1.4

%

  
Biogen, Inc. – Biotechnology    

1.4

%

  
Bristol-Myers Squibb Co. – Pharmaceuticals    

1.4

%

  
Abbott Laboratories – Health Care Equipment & Supplies    

1.2

%

  
Intra-Cellular Therapies, Inc. – Pharmaceuticals    

1.2

%

  
Guardant Health, Inc. – Health Care Equipment & Supplies    

1.1

%

  

Fund Performance

HQH is a closed-end fund which invests predominantly in healthcare companies. Subject to regular consideration, the Trustees of HQH have instituted a policy of making quarterly distributions to shareholders. The Fund seeks to make such distributions in the form of long-term capital gains.

The Fund considers investments in companies of all sizes and in all healthcare subsectors, including but not limited to, biotechnology, pharmaceuticals, healthcare equipment, healthcare supplies, life science tools and services, healthcare distributors, managed healthcare, healthcare technology, and healthcare facilities. The Fund emphasizes innovation, investing both in public and pre-public venture companies. The Fund considers its venture investments to be a differentiating characteristic. Among the various healthcare subsectors, HQH has considered the biotechnology subsector, including both pre-public and public companies, to be a key contributor to the healthcare sector. The Fund holds biotech assets, including both public and pre-public, often representing 50-65% of net assets.


5

There is no commonly published index which matches the investment strategy of HQH. The S&P Composite 1500® Health Care Index* (S15HLTH) consists of approximately 180 companies representing most or all of the healthcare subsectors in which HQH typically invests; biotechnology often represents 15-20% of this index. By contrast, the NASDAQ Biotechnology Index®* (NBI), which contains roughly 370 constituents, is much more narrowly constructed. The vast majority of this index is comprised of biotechnology, pharmaceutical and life science tools companies. In recent years, biotechnology has often represented 72-82% of the NBI. Neither the S15HLTH nor NBI indices contain any material amount of pre-public company assets.

Given the circumstances, we present both NAV and stock returns for the Fund in comparison to several commonly published indices. One index, the S&P 500 Index®* (SPX), is a commonly considered broad based index; this index is comprised of companies in many areas of the economy, including, but not limited to healthcare. As described above, the NBI is a healthcare index mostly focused in three healthcare sectors with a high level of biotechnology by comparison. The S15HLTH contains a wider representation of healthcare subsectors, but typically contains a much lower biotechnology composition.

HQH generally invests in a combination of large-cap growth-oriented and earlier stage innovative healthcare companies with a focus on the biotechnology sector. Generally, HQH targets biotechnology exposure below that of the NBI and a higher biotechnology exposure than that of the S15HLTH. We note that, in recent periods, biotechnology has been a significant contributor to returns (both positive and negative) associated with those indices. We believe this sector continues to have significant potential for growth in the future.

Fund Performance for the Period Ending March 31, 2022

Period

  

HQH NAV

  

HQH MKT

  

NBI

  

S15HLTH

  

SPX

  
6 month    

-9.96

      

-15.09

      

-17.72

      

7.11

      

5.91

    
1 year    

-4.57

      

-7.52

      

-11.16

      

17.20

      

15.63

    
5 year    

6.47

      

6.06

      

6.93

      

15.11

      

15.98

    
10 year    

11.37

      

11.67

      

13.06

      

16.01

      

14.63

    


6

Change in the value of a $10,000 investment

Cumulative total return from 3/31/2012 to 3/31/2022

All performance over one-year has been annualized. Performance data quoted represents past performance, which is no guarantee of future results, and current performance may be lower or higher than the figures shown. The NAV total return takes into account the Fund's total annual expenses and does not reflect transaction charges. If transaction charges were reflected, NAV total return would be reduced. All distributions are assumed to be reinvested either in accordance with the dividend reinvestment plan (DRIP) for market price returns or NAV for NAV returns. Until the DRIP price is available from the Plan Agent, the market price returns reflect the reinvestment at the closing market price on the last business day of the month. Once the DRIP is available around mid-month, the market price returns are updated to reflect reinvestment at the DRIP price. The graph and table do not reflect the deduction of taxes a shareholder would pay on fund distributions or the sale of fund shares. The Risk Adjusted NASDAQ Biotechnology Index® computed by Tekla using Bloomberg data for the NBI and applying the fund's computed 0.90 beta to NBI performance to reflect the fund's lower historical risk.

Portfolio Management Commentary

Fund and Benchmark Performance and Other Influencing Factors

For the 6-month period ending March 31, 2022, the Fund net asset value was down 10.0% and market value down 15.1%. Over the same period the NBI declined 17.7% and the S15HLTH was up 7.1% percent.

The largest positive contribution to Fund relative performance was an underweight allocation to the small and midcap biotechnology subsector that generally underperformed as well as being overweight several individual companies that outperformed. Two overweight positions in the period that contributed positively to performance were McKesson Corp. (MCK), up 54%, and Intra-Cellular Therapies, Inc. (ITCI), up 64%. McKesson Corp., a leading health care distributor, saw its stock price outperform as investors sought defensive investments and appreciated its moderate valuation and stable earnings growth history. Intra-Cellular Therapies stock outperformed due to strong initial sales for Caplyta, which was recently approved in a new indication, bipolar depression. A large underweight position helping fund performance was Moderna, Inc., which fell 55% in the period as investors more appreciated the Company's


7

declining recurring revenue from COVID-19 vaccines. The Fund benefited from an underweight allocation to small and midcap biotechnology companies, which returned -56% and -26% respectively in the past 6 months.

The largest negative contribution to Fund relative performance was due to being underweight in several companies that outperformed and to maintaining an underweight allocation to the Pharmaceutical sub sector which outperformed. Two overweight positions in the period that contributed negatively to performance were Guardant Health, Inc. (GH), down 47%, and Rallybio Corp. (RLYB), down 60% in the past six months. Guardant Health, a leading company developing a novel liquid biopsy test to detect colon cancer, suffered a large stock price decline similar to peer companies whose valuation depends on high future sales growth. Rallybio is typical among the group of early stage biotechs that underperformed in the period as investors shied away from companies with uncertain value-inflecting clinical milestones farther off in the future. One underweight position in the period that contributed negatively to relative performance was AstraZeneca plc (AZN), up 12%. Pharmaceutical companies like AstraZeneca outperformed in the period reflecting a shift in investor sentiment to favor large, low valuation companies with near-term revenue certainty. While the pharmaceutical stocks in the portfolio outperformed those in the benchmark or had positive stock selection, the Fund lost performance versus the benchmark due to a lower allocation.

Portfolio Highlights as of March 31, 2022

Among other investments, Tekla Healthcare Investors' performance benefited in the past six months by the following:

Moderna, Inc. (MRNA) is a vaccine company based on a new therapeutic modality, messenger RNA. The Company has multiple development programs in the clinic but is most well-known for its commercially successful vaccine candidate targeting the COVID-19 virus. At its peak in summer 2021, Moderna had a market capitalization of nearly $200 billion with roughly $20 billion in COVID-19 vaccines sales expected for 2021 and 2022. While the future path of the COVID-19 pandemic is uncertain, we decided the valuation for Moderna reflected too much optimism on the recurring nature of the booster vaccine business in the next decade. The Fund was underweight MRNA in the report period as its stock price declined sharply in accordance with diminished expectations for vaccine sales.

McKesson Corp. (MCK) distributes pharmaceutical and medical-surgical supplies and also provides specialty pharmacy and biopharma services.


8

The Company was selected by the U.S. government to distribute COVID-19 vaccines and supplies which helped accelerate earnings growth during the pandemic. Investor sentiment has also improved thanks to better visibility around the Company's opioid liability exposure. The Fund was overweight MCK, which delivered strong stock gains during the reporting period.

Intra-Cellular Therapies, Inc. (ITCI) is a mid-cap pharmaceutical company that markets Caplyta (lumateperone), an atypical antipsychotic with better tolerability than other agents in this class. Originally approved for the treatment of schizophrenia in 2019, Caplyta received a second FDA nod for bipolar depression in December 2021 and had a strong initial launch in this larger indication. The Fund has maintained an overweight position in this stock.

Among other examples, Tekla Healthcare Investors' performance was negatively impacted by the following investments:

AstraZeneca PLC (AZN) is a large multinational pharmaceutical company with geographic sales exposure across developed and emerging markets in cancer and autoimmune therapeutics and also distributes a COVID-19 vaccine at cost. Along with other large cap biopharma companies, AZN had strong performance in the first quarter of 2022 and we have been underweight the stock.

Guardant Health, Inc. (GH) is a leading precision oncology company focused on using liquid biopsy for cancer detection and diagnostics through its proprietary blood tests, vast data sets, and advanced analytics. The Fund has maintained an overweight position in the stock as we are positive on a key upcoming readout for its colon cancer test. The underperformance of the stock was mainly driven by the correction of life science stocks, particularly those with a valuation dependent on high future sales growth.

Rallybio Corp. (RLYB) is a clinical stage biotechnology company developing therapies for patients with severe and rare disorders. Its lead candidate, RLYB212, is a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare condition with no currently approved therapies. RLYB completed a successful IPO in August 2021. However, since then, investor sentiment has shifted away from pre-commercial Companies with limited near-term catalysts. As a result, the company's stock underperformed in the period while the Fund was overweight.

*The trademarks NASDAQ Biotechnology Index®, S&P Composite 1500® Health Care Index, SPDR® S&P® Biotech ETF and S&P 500® Index referenced in this report are the property of their respective owners. These trademarks are not owned by or associated with the Fund or its service providers, including Tekla Capital Management LLC.


9

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited)

SHARES

   CONVERTIBLE PREFERRED
(Restricted) (a) (b) - 7.0% of Net Assets		  

VALUE

  
   

Biotechnology - 4.4%

  
 

326,667

    

Amphivena Therapeutics, Inc. Series B, 6.00% (c)

  

$

33

    
 

525,972

    

Amphivena Therapeutics, Inc. Series C, 6.00% (c)

    

53

    
 

82,076

    

Arbor Biotechnologies, Series B, 8.00%

    

1,359,999

    
 

2,353,932

    

Arkuda Therapeutics, Inc. Series A, 6.00% (c)

    

4,162,222

    
 

487,526

    

Arkuda Therapeutics, Inc. Series B, 6.00% (c)

    

862,043

    
 

602,572

    

Dynacure Series C

    

2,766,370

    
 

2,875,000

    

Hotspot Therapeutics, Inc. Series B, 6.00%

    

9,317,587

    
 

632,394

    

HotSpot Therapeutics, Inc. Series C, 6.00%

    

2,049,526

    
 

1,020,000

    

ImmuneID, Inc. Series A, 8.00%

    

2,040,000

    
 

7,187,500

    

Invetx, Inc. Series A, 8.00% (c)

    

4,816,344

    
 

3,089,091

    

Invetx, Inc. Series B, 8.00% (c)

    

2,070,000

    
 

277,444

    

Oculis SA, Series B2, 6.00%

    

2,952,004

    
 

75,367

    

Oculis SA, Series C, 6.00%

    

801,905

    
 

528,339

    

Parthenon Therapeutics, Inc. Series A

    

2,092,307

    
 

346,666

    

Priothera Ltd. Series A, 6.00% (c)

    

3,834,992

    
 

1,553,631

    

Quell Therapeutics, Series B (d)

    

2,936,363

    
 

294,589

    

ReCode Therapeutics, Series B, 5.00%

    

2,719,999

    
     

44,781,747

    
    Health Care Equipment & Supplies (b) - 0.1%  
 

421,634

    

IO Light Holdings, Inc. Series A2

    

1,423,015

    
     

1,423,015

    
    Pharmaceuticals (b) - 2.5%  
 

616,645

    

Aristea Therapeutics, Inc. Series B, 8.00%

    

3,399,996

    
 

1,295,238

    

Biotheryx, Inc. Series E, 8.00%

    

6,800,000

    
 

17,547,740

    

Curasen Therapeutics, Inc. Series A (c)

    

8,414,141

    
 

657,322

    

Endeavor Biomedicines, Inc. Series B, 8.00%

    

3,099,996

    
 

2,773,472

    

HiberCell, Inc. Series B

    

3,399,999

    
     

25,114,132

    
        TOTAL CONVERTIBLE PREFERRED
(Cost $78,248,525)		    

71,318,894

    
PRINCIPAL
AMOUNT		   CONVERTIBLE NOTES (Restricted) (a) (b) (c) - 0.0%
of Net Assets		      
   

Biotechnology - 0.0%

  

$

303,323

    

Amphivena Therapeutics, Inc., 8.00%

   

0

    
        TOTAL CONVERTIBLE NOTES
(Cost $303,323)		    

0

    

The accompanying notes are an integral part of these financial statements.
10

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited, continued)

SHARES

  

COMMON STOCKS - 88.7% of Net Assets

  

VALUE

  
   

Biotechnology - 47.9%

  
 

113,481

    

AbbVie, Inc.

  

$

18,396,405

    
 

367,414

    

Affimed N.V. (a) (d)

    

1,605,599

    
 

90,398

    

Alkermes plc (a)

    

2,378,371

    
 

91,924

    

Alnylam Pharmaceuticals, Inc. (a)

    

15,010,270

    
 

323,595

    

Amgen, Inc.

    

78,251,743

    
 

129,695

    

Apellis Pharmaceuticals, Inc. (a)

    

6,589,803

    
 

86,869

    

Arcutis Biotherapeutics, Inc. (a)

    

1,673,097

    
 

21,958

    

Argenx SE ADR (a)

    

6,923,577

    
 

87,937

    

Arrowhead Pharmaceuticals, Inc. (a)

    

4,044,223

    
 

43,409

    

Ascendis Pharma A/S ADR (a)

    

5,094,480

    
 

30,066

    

BeiGene Ltd. ADR (a)

    

5,670,448

    
 

137,035

    

BioCryst Pharmaceuticals, Inc. (a)

    

2,228,189

    
 

66,310

    

Biogen, Inc. (a)

    

13,964,886

    
 

28,433

    

Biohaven Pharmaceutical Holding Co., Ltd. (a)

    

3,371,301

    
 

71,154

    

BioMarin Pharmaceutical, Inc. (a)

    

5,485,973

    
 

57,580

    

BioNTech SE ADR (a)

    

9,820,845

    
 

90,404

    

Black Diamond Therapeutics, Inc. (a) (e)

    

250,419

    
 

67,726

    

Blueprint Medicines Corp. (a)

    

4,326,337

    
 

475,576

    

Caribou Biosciences, Inc. (a)

    

4,365,788

    
 

51,708

    

ChemoCentryx, Inc. (a)

    

1,296,319

    
 

143,592

    

Denali Therapeutics, Inc. (a)

    

4,619,355

    
 

15,094

    

Fate Therapeutics, Inc. (a)

    

585,194

    
 

15,186

    

Fusion Pharmaceuticals, Inc. (a) (d)

    

117,995

    
 

200,492

    

G1 Therapeutics, Inc. (a) (e)

    

1,523,739

    
 

296,462

    

Galera Therapeutics, Inc. (a)

    

705,579

    
 

854,746

    

Gilead Sciences, Inc.

    

50,814,650

    
 

53,885

    

I-Mab ADR (a)

    

875,092

    
 

36,800

    

Intellia Therapeutics, Inc. (a)

    

2,674,256

    
 

33,437

    

Intercept Pharmaceuticals, Inc. (a) (e)

    

544,020

    
 

112,999

    

Ionis Pharmaceuticals, Inc. (a)

    

4,185,483

    
 

67,254

    

Karuna Therapeutics, Inc. (a)

    

8,527,135

    
 

1,063,799

    

Mereo Biopharma Group plc ADR (a)

    

1,191,455

    
 

138,636

    

Moderna, Inc. (a)

    

23,881,437

    
 

205,800

     Moonlake Immunotherapeutics AG,
Class A (Restricted) (a) (b)		    

1,852,200

    
 

81,617

    

Neurocrine Biosciences, Inc. (a)

    

7,651,594

    
 

2,970

    

NexGel, Inc. (a)

    

5,673

    
 

37,188

    

Novavax, Inc. (a) (e)

    

2,738,896

    
 

51,406

    

Praxis Precision Medicines, Inc. (a)

    

524,855

    
 

154,807

    

Precision BioSciences, Inc. (a)

    

476,805

    
 

389,846

    

Pyxis Oncology, Inc. (Restricted) (a) (b)

    

1,417,480

    
 

91,800

    

Pyxis Oncology, Inc. (a) (e)

    

370,872

    

The accompanying notes are an integral part of these financial statements.
11

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited, continued)

SHARES

  

Biotechnology - continued

  

VALUE

  
 

957,065

    

Rallybio Corp. (a) (e)

  

$

6,680,314

    
 

81,960

    

Regeneron Pharmaceuticals, Inc. (a)

    

57,242,503

    
 

106,483

    

Sarepta Therapeutics, Inc. (a)

    

8,318,452

    
 

68,117

    

Scholar Rock Holding Corp. (a)

    

878,028

    
 

168,857

    

Seagen, Inc. (a)

    

24,323,851

    
 

115,649

    

Sutro Biopharma, Inc. (a)

    

950,635

    
 

142,714

    

Travere Therapeutics, Inc. (a)

    

3,677,740

    
 

138,057

    

TScan Therapeutics, Inc. (a)

    

386,560

    
 

80,403

    

Ultragenyx Pharmaceutical, Inc. (a)

    

5,838,866

    
 

357,080

    

uniQure N.V. (d) (a)

    

6,452,436

    
 

42,183

    

United Therapeutics Corp. (a)

    

7,568,052

    
 

567,550

    

Vectivbio Holding AG (a)

    

2,667,485

    
 

198,944

    

Vertex Pharmaceuticals, Inc. (a)

    

51,918,416

    
 

79,511

    

Xencor, Inc. (a)

    

2,121,353

    
 

27,684

    

Zai Lab Ltd. ADR (a)

    

1,217,542

    
     

486,274,071

    
   

Health Care Equipment & Supplies - 6.9%

  
 

106,073

    

Abbott Laboratories

    

12,554,800

    
 

160,000

    

Cercacor Laboratories, Inc. (Restricted) (a) (b)

    

778,215

    
 

3,816

    

DexCom, Inc. (a)

    

1,952,266

    
 

43,827

    

Edwards Lifesciences Corp. (a)

    

5,159,314

    
 

173,673

    

Guardant Health, Inc. (a)

    

11,504,100

    
 

10,945

    

Hologic, Inc. (a)

    

840,795

    
 

15,824

    

IDEXX Laboratories, Inc. (a)

    

8,656,678

    
 

36,792

    

Medtronic plc

    

4,082,072

    
 

74,215

    

Stryker Corp.

    

19,841,380

    
 

39,439

    

Zimmer Biomet Holdings, Inc.

    

5,044,248

    
 

3,943

    

Zimvie Inc. (a)

    

90,058

    
     

70,503,926

    
   

Health Care Providers & Services - 6.7%

  
 

17,832

    

Addus HomeCare Corp. (a)

    

1,663,547

    
 

29,482

    

AMN Healthcare Services, Inc. (a)

    

3,075,857

    
 

2,644

    

Anthem, Inc.

    

1,298,786

    
 

18,681

    

Charles River Laboratories International, Inc. (a)

    

5,304,843

    
 

41,860

    

Cigna Corp.

    

10,030,075

    
 

51,696

    

Contra Zogenix, Inc. CVR (a) (b)

    

78,578

    
 

24,237

    

HCA Healthcare, Inc.

    

6,074,277

    
 

47,561

    

HealthEquity, Inc. (a)

    

3,207,514

    
 

6,740

    

Humana, Inc.

    

2,933,046

    
 

222,222

    

InnovaCare, Inc. Escrow Shares (Restricted) (a) (b)

    

57,444

    
 

6,524

    

Medpace Holdings, Inc. (a)

    

1,067,261

    
 

20,567

    

Molina Healthcare, Inc. (a)

    

6,860,945

    

The accompanying notes are an integral part of these financial statements.
12

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited, continued)

SHARES

  

Health Care Providers & Services - continued

  

VALUE

  
 

107,595

    

Owens & Minor, Inc.

  

$

4,736,332

    
 

43,179

    

UnitedHealth Group, Inc.

    

22,019,995

    
     

68,408,500

    
    Healthcare Services (a) - 1.8%  
 

15,929

    

Laboratory Corporation of America Holdings

    

4,199,840

    
 

173,530

    

Syneos Health, Inc.

    

14,047,254

    
     

18,247,094

    
       

Life Sciences Tools & Services - 6.8%

      
 

216,209

    

Adaptive Biotechnologies Corp. (a)

    

3,000,981

    
 

35,350

    

ICON plc (a)

    

8,597,827

    
 

126,722

    

Illumina, Inc. (a)

    

44,276,667

    
 

10,514

    

PerkinElmer, Inc.

    

1,834,272

    
 

14,873

    

Thermo Fisher Scientific, Inc.

    

8,784,738

    
 

8,360

    

Waters Corp. (a)

    

2,594,860

    
     

69,089,345

    
   

Medical Devices and Diagnostics - 1.5%

  
 

4,063

    

Align Technology, Inc. (a)

    

1,771,468

    
 

126,126

    

Boston Scientific Corp. (a)

    

5,586,121

    
 

24,181

    

Danaher Corp.

    

7,093,013

    
 

3,402

    

Intuitive Surgical, Inc. (a)

    

1,026,315

    
     

15,476,917

    
   

Pharmaceuticals - 16.9%

  
 

51,378

    

Arvinas, Inc. (a)

    

3,457,739

    
 

354,157

    

AstraZeneca plc ADR

    

23,494,775

    
 

104,219

    

Aurinia Pharmaceuticals, Inc. (a) (d)

    

1,290,231

    
 

188,556

    

Bristol-Myers Squibb Co.

    

13,770,245

    
 

37,913

    

Eli Lilly & Co.

    

10,857,146

    
 

465,507

    

Endo International plc (a) (d)

    

1,075,321

    
 

465,204

    

Horizon Therapeutics plc (a)

    

48,944,113

    
 

202,967

    

Intra-Cellular Therapies, Inc. (a)

    

12,419,551

    
 

22,510

    

IQVIA Holdings, Inc. (a)

    

5,204,537

    
 

65,411

    

Jazz Pharmaceuticals plc (a) (d)

    

10,182,530

    
 

36,231

    

Johnson & Johnson

    

6,421,220

    
 

48,115

    

McKesson Corp.

    

14,729,445

    
 

71,668

    

Merck & Co., Inc.

    

5,880,359

    
 

55,093

    

Mirati Therapeutics, Inc. (a)

    

4,529,747

    
 

7,050

    

Perrigo Co. plc

    

270,932

    
 

60,450

    

Pfizer, Inc.

    

3,129,496

    
 

79,790

    

Spectrum Pharmaceuticals, Inc. (a)

    

102,929

    

The accompanying notes are an integral part of these financial statements.
13

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited, continued)

SHARES

  

Pharmaceuticals - continued

  

VALUE

  
 

28,747

    

Tetraphase Pharmaceuticals, Inc. CVR (a) (b)

  

$

1,725

    
 

291,666

    

Teva Pharmaceutical Industries Ltd. ADR (a)

    

2,738,744

    
 

69,000

    

Theseus Pharmaceuticals, Inc. (a) (e)

    

795,570

    
 

94,775

    

VYNE Therapeutics, Inc. (a) (e)

    

61,613

    
 

12,377

    

Zoetis, Inc.

    

2,334,178

    
     

171,692,146

    
    Special Purpose Acquisition Company (a) - 0.2%  
 

171,597

    

Helix Acquisition Corp.

    

1,904,727

    
        TOTAL COMMON STOCKS
(Cost $717,342,881)		    

901,596,726

    
        EXCHANGE TRADED FUND (e) - 0.6%
of Net Assets		          
 

65,994

    

SPDR S&P Biotech ETF

    

5,931,541

    
        TOTAL EXCHANGE TRADED FUND
(Cost $6,199,405)		    

5,931,541

    
PRINCIPAL
AMOUNT		  

SHORT-TERM INVESTMENTS - 3.4% of Net Assets

      

$

23,495,000

     Repurchase Agreement, Fixed Income Clearing
Corp., repurchase value $23,495,000, 0.00%,
dated 03/31/22, due 04/01/22 (collateralized
by U.S. Treasury Note 1.50%, due 11/30/28,
market value $23,964,962)		    

23,495,000

    

SHARES

          
 

11,515,977

     State Street Institutional U.S. Government Money
Market Fund, Institutional Class, 0.22% (f)		    

11,515,977

    
        TOTAL SHORT-TERM INVESTMENTS
(Cost $35,010,977)		    

35,010,977

    
        TOTAL INVESTMENTS BEFORE MILESTONE
INTERESTS - 99.7%
(Cost $837,105,111)		    

1,013,858,138

    

The accompanying notes are an integral part of these financial statements.
14

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2022

(Unaudited, continued)

INTERESTS

   MILESTONE INTERESTS (Restricted) (a) (b) - 1.0%
of Net Assets		  

VALUE

  
   

Biotechnology - 0.2%

  
 

1

    

Rainier Therapeutics Milestone Interest

  

$

421,161

    
 

1

    

Therachon Milestone Interest

    

1,316,666

    
     

1,737,827

    
   

Health Care Equipment & Supplies - 0.0%

  
 

1

    

Therox Milestone Interest

    

1,982

    
   

Pharmaceuticals - 0.8%

  
 

1

    

Afferent Milestone Interest

    

295,365

    
 

1

    

Ethismos Research Milestone Interest

    

0

    
 

1

    

Impact Biomedicines Milestone Interest

    

1,765,258

    
 

1

    

Neurovance Milestone Interest

    

5,897,886

    
     

7,958,509

    
        TOTAL MILESTONE INTERESTS
(Cost $8,061,450)		    

9,698,318

    
        TOTAL INVESTMENTS - 100.7%
(Cost $845,166,561)		    

1,023,556,456

    
        OTHER LIABILITIES IN EXCESS OF
ASSETS - (0.7)%		    

(6,615,267

)

  
       

NET ASSETS - 100%

  

$

1,016,941,189

    

(a)    Non-income producing security.

(b)    Security fair valued using significant unobservable inputs. See Investment Valuation and Fair Value Measurements.

(c)    Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of $24,159,828).

(d)    Foreign security.

(e)    All or a portion of this security is on loan as of March 31, 2022.

(f)    This security represents the investment of cash collateral received for securities lending and is a registered investment company advised by State Street Global Advisors. The rate shown is the annualized seven-day yield as of March 31, 2022.

ADR  American Depository Receipt

CVR  Contingent Value Right

The accompanying notes are an integral part of these financial statements.
15

TEKLA HEALTHCARE INVESTORS

STATEMENT OF ASSETS AND LIABILITIES

MARCH 31, 2022

(Unaudited)

ASSETS:

  
Investments in unaffiliated issuers, at value
including $11,111,831 of securities loaned
(cost $805,560,389) 		 

$

989,698,310

    
Investments in affiliated issuers, at value
(cost $31,544,722)		    

24,159,828

    

Milestone interests, at value (cost $8,061,450)

    

9,698,318

    

Total investments

    

1,023,556,456

    

Cash

    

7

    

Foreign currency, at value (cost $58)

    

55

    

Dividends and interest receivable

    

288,483

    

Securities lending income receivable

    

11,444

    

Receivable for investments sold

    

5,884,045

    

Prepaid expenses

    

58,465

    

Other assets (see Note 1)

    

5,166

    

Total assets

    

1,029,804,121

    

LIABILITIES:

  

Payable upon return of securities loaned

    

11,515,977

    

Accrued advisory fee

    

839,548

    

Accrued investor support service fees

    

39,576

    

Accrued shareholder reporting fees

    

80,699

    

Accrued other

    

387,132

    

Total liabilities

    

12,862,932

    

Commitments and Contingencies (see Notes 1 and 5)

  

NET ASSETS

  

$

1,016,941,189

    

SOURCES OF NET ASSETS:

  
Shares of beneficial interest, par value $.01 per share,
unlimited number of shares authorized, amount
paid in on 46,343,900 shares issued and outstanding		  

$

463,439

    

Additional paid-in-capital

    

873,599,121

    

Total distributable earnings (loss)

    

142,878,629

    
Total net assets (equivalent to $21.94 per share
based on 46,343,900 shares outstanding)		  

$

1,016,941,189

    

The accompanying notes are an integral part of these financial statements.
16

TEKLA HEALTHCARE INVESTORS

STATEMENT OF OPERATIONS

SIX MONTHS ENDED MARCH 31, 2022

(Unaudited)

INVESTMENT INCOME:

  

Dividend income

  

$

3,808,926

    

Interest and other income

    

12,072

    

Securities lending

    

134,717

    

Total investment income

    

3,955,715

    

EXPENSES:

  

Advisory fees

    

5,229,845

    

Investor support service fees

    

260,655

    

Administration fees

    

122,603

    

Legal fees

    

95,814

    

Custodian fees

    

95,008

    

Shareholder reporting

    

83,644

    

Trustees' fees and expenses

    

76,368

    

Auditing fees

    

59,276

    

Transfer agent fees

    

28,981

    

Other (see Note 2)

    

140,949

    

Total expenses

    

6,193,143

    

Net investment loss

    

(2,237,428

)

  

REALIZED AND UNREALIZED GAIN (LOSS):

  

Net realized gain (loss) on:

  

Investments in unaffiliated issuers

    

7,012,630

    

Closed or expired option contracts written

    

7,619,045

    

Foreign currency transactions

    

5,493

    

Net realized gain

    

14,637,168

    

Net change in unrealized appreciation (depreciation) on:

  

Investments in unaffiliated issuers

    

(124,273,600

)

  

Investments in affiliated issuers

    

2,525,762

    

Milestone interests

    

(1,351,238

)

  

Option contracts written

    

(4,349,159

)

  

Foreign currency

    

(3

)

  

Net change in unrealized appreciation (depreciation)

    

(127,448,238

)

  

Net realized and unrealized gain (loss)

    

(112,811,070

)

  
Net decrease in net assets resulting from
operations		  

($

115,048,498

)

  

The accompanying notes are an integral part of these financial statements.
17

TEKLA HEALTHCARE INVESTORS

STATEMENTS OF CHANGES IN NET ASSETS

    Six months ended
March 31, 2022
(Unaudited)		   Year ended
September 30,
2021		  
NET INCREASE (DECREASE) IN NET
ASSETS RESULTING FROM OPERATIONS:		  

Net investment loss

  

($

2,237,428

)

  

($

6,230,384

)

  

Net realized gain

    

14,637,168

      

82,529,358

    
Change in net unrealized appreciation
(depreciation)		    

(127,448,238

)

    

78,876,879

    
Net increase (decrease) in net
assets resulting from operations		    

(115,048,498

)

    

155,175,853

    
DISTRIBUTIONS TO SHAREHOLDERS
(See Note 1):		    

(45,175,606

)

    

(91,590,428

)

  

CAPITAL SHARE TRANSACTIONS:

  
Reinvestment of distributions
(918,432 and 1,553,813 shares,
respectively)		    

20,263,209

      

38,621,063

    

Total capital share transactions

    

20,263,209

      

38,621,063

    
Net increase (decrease) in
net assets		    

(139,960,895

)

    

102,206,488

    

NET ASSETS:

  

Beginning of period

    

1,156,902,084

      

1,054,695,596

    

End of period

  

$

1,016,941,189

    

$

1,156,902,084

    

The accompanying notes are an integral part of these financial statements.
18

TEKLA HEALTHCARE INVESTORS

FINANCIAL HIGHLIGHTS

    Six months
ended
March 31, 2022		  

For the years ended September 30,

  
   

(Unaudited)

  

2021

  

2020

  

2019

  

2018

  

2017

  
OPERATING PERFORMANCE FOR A SHARE
OUTSTANDING THROUGHOUT EACH PERIOD		  
Net asset value per share,
beginning of period		  

$

25.47

    

$

24.04

    

$

20.33

    

$

25.62

    

$

26.02

    

$

24.99

    

Net investment loss (1)

    

(0.05

)

    

(0.14

)

    

(0.05

)

    

(0.07

)

    

(0.10

)

    

(0.13

)

  
Net realized and unrealized
gain (loss)		    

(2.49

)

    

3.63

      

5.50

      

(3.46

)

    

1.63

      

3.12

    
Total increase (decrease)
from investment operations		    

(2.54

)

    

3.49

      

5.45

      

(3.53

)

    

1.53

      

2.99

    

Distributions to shareholders from:

  

Net investment income

    

—

      

(0.61

)

    

(0.01

)

    

(0.17

)

    

(0.15

)(2)

    

—

    

Net realized capital gains

    

(0.99

)

    

(1.45

)

    

(1.77

)

    

(1.65

)

    

(1.79

)(2)

    

(1.96

)

  

Total distributions

    

(0.99

)

    

(2.06

)

    

(1.78

)

    

(1.82

)

    

(1.94

)

    

(1.96

)

  
Increase resulting from
shares repurchased (1)		    

—

      

—

      

0.04

      

0.06

      

0.01

      

—

(3)

  
Net asset value per share,
end of period		  

$

21.94

    

$

25.47

    

$

24.04

    

$

20.33

    

$

25.62

    

$

26.02

    
Per share market value,
end of period		  

$

20.77

    

$

25.57

    

$

20.62

    

$

18.34

    

$

23.15

    

$

25.23

    
Total investment return
at market value		    

(15.09

%)*

    

34.64

%

    

23.38

%

    

(12.88

%)

    

0.05

%

    

14.95

%

  
Total investment return
at net asset value		    

(9.96

%)*

    

15.03

%

    

29.77

%

    

(12.74

%)

    

7.37

%

    

12.95

%

  

RATIOS

  
Net investment loss to average
net assets		    

(0.42

%)**

    

(0.54

%)

    

(0.20

%)

    

(0.31

%)

    

(0.41

%)

    

(0.53

%)

  

Expenses to average net assets

    

1.17

%**

    

1.11

%

    

1.10

%

    

1.12

%

    

1.08

%

    

1.10

%

  

SUPPLEMENTAL DATA

  
Net assets at end of period
(in millions)		  

$

1,017

    

$

1,157

    

$

1,055

    

$

871

    

$

1,082

    

$

1,058

    

Portfolio turnover rate

    

22.11

%*

    

69.19

%

    

52.44

%

    

47.65

%

    

45.75

%

    

29.21

%

  

*  Not annualized.

**  Annualized.

(1)  Computed using average shares outstanding.

(2)  Amount previously presented incorrectly as solely distributions from net realized capital gains has been revised to reflect the proper classification.

(3)  Amount represents less than $0.005 per share.

The accompanying notes are an integral part of these financial statements.
19

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(Unaudited)

(1)  Organization and Significant Accounting Policies

Tekla Healthcare Investors (the Fund) is a Massachusetts business trust formed on October 31, 1986 and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund commenced operations on April 22, 1987. The Fund's investment objective is long-term capital appreciation through investment in U.S. and foreign companies in the healthcare industry. The Fund invests primarily in securities of public and private companies that are believed by the Fund's Investment Adviser, Tekla Capital Management LLC (the Adviser), to have significant potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers that are traded primarily in foreign markets.

The preparation of these financial statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual results could differ from these estimates and such differences could be material. The following is a summary of significant accounting policies followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America (GAAP). The Fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board Accounting Standards Codification 946. Events or transactions occurring after March 31, 2022, through the date that the financial statements were issued, have been evaluated in the preparation of these financial statements.

Beginning in January 2020, global financial markets have experienced, and may continue to experience, significant volatility resulting from the spread of a virus known as COVID-19. The outbreak of COVID-19 has resulted in travel and border restrictions, quarantines, supply chain disruptions, lower consumer demand, and general market uncertainty. The effects of COVID-19 have adversely affected, and may continue to adversely affect, the global economy, the economies of certain nations, and individual issuers, all of which may negatively impact the Fund's performance.

The market value of the Fund's investments will move up and down, sometimes rapidly and unpredictably, based upon political, regulatory, market, economic, and social conditions, as well as developments that impact specific economic sectors, industries, or segments of the market, including conditions that directly


20

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

relate to the issuers of the Fund's investments, such as management performance, financial condition, and demand for the issuers' goods and services. The Fund is subject to the risk that geopolitical events will adversely affect global economies and markets. War, terrorism, and related geopolitical events have led, and in the future may lead, to increased short-term market volatility and may have adverse long-term effects on global economies and markets. Likewise, natural and environmental disasters and epidemics or pandemics may be highly disruptive to economies and markets. This means that the Fund may lose money on its investment due to unpredictable drops in a security's value or periods of below-average performance in a given security or in the securities market as a whole.

Investment Valuation

Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price, as of the close of trading, generally 4 p.m., Eastern Time. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by the Adviser also using fair valuation policies and procedures approved by the Trustees described below. Non-exchange traded warrants of publicly traded companies are generally valued using the Black-Scholes model, which incorporates both observable and unobservable inputs. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.

Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.


21

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these financial statements.

Milestone Interests

The Fund holds financial instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The milestone interests were received as part of the proceeds from the sale of seven private companies. Any payments received are treated as a reduction of the cost basis of the milestone interests with payments received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the milestone interests provide for payments at various stages of the development of Afferent, Ethismos Research, Neurovance, Impact Biomedicines, Therachon, Rainier Therapeutics, Inc., and Therox's principal product candidate as of the date of the sale.


22

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

The following is a summary of the impact of the milestone interests on the financial statements as of and for the six months ended March 31, 2022:

Statement of Assets and Liabilities, Milestone interests, at value

  

$

9,698,318

    

Statement of Assets and Liabilities, Total distributable earnings

  

$

1,636,868

    
Statement of Operations, Change in unrealized appreciation (depreciation)
on Milestone interests		  

($

1,351,237

)

  

Options on Securities

An option contract is a contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.

The Fund's obligation under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price or in the absence of a sale, the mean between the closing bid and asked prices. Gain or loss is recognized when the option contract expires, is exercised or is closed.

If the Fund writes a covered call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the market value of the underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential inability of counterparties to meet the terms of their contracts. The Fund's maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may arise upon entering into option contracts including the risk that an illiquid secondary market will limit the Fund's ability to close out an option contract prior to the expiration date and that a change in the value of the option contract may not correlate exactly with changes in the value of the securities or currencies hedged.

All options on securities and securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the securities subject to the option or may maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least


23

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

equal to the market value of the securities underlying the option. When the Fund writes a put option, this means that the Fund will maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price of the option.

The average number of outstanding put options purchased and call options written for the six months ended March 31, 2022 were 725 and 725, respectively.

Derivatives not accounted
for as hedging instruments
under ASC 815

  

Statement of Assets and
Liabilities Location

  

Statement of Operations Location

  

Equity Contracts
 

          

Assets, Investments,
at value

  


$—  

  

Net realized gain on
investments

 

$95,213

  

 
 
 

          

 
 
 

  

 
 
 

  

Change in unrealized
appreciation (depreciation)
on investments

  

$1,465,848

  

  
 
 

          

Liabilities, options
written, at value
 

  


$—
 

  

Net realized gain (loss) on
closed or expired option
contracts written

  

$7,619,045

  

 
 
 

          

 
 
 

  

 
 
 

  

Change in unrealized
appreciation (depreciation)
on option contracts written

 

($4,349,159)

  

Other Assets

Other assets in the Statement of Assets and Liabilities consists of amounts due to the Fund at various times in the future in connection with the sale of investments in two private companies.

Investment Transactions and Income

Investment transactions are recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the ex-dividend date, less any foreign taxes withheld. Upon notification from issuers, some of the dividend income received may be redesignated as a reduction of cost of the related investment if it represents a return of capital.

The aggregate cost of purchases and proceeds from sales of investment securities (other than short-term investments) for the six months ended March 31, 2022 totaled $231,783,435 and $276,368,361, respectively.


24

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

Securities Lending

The Fund may lend its securities to approved borrowers to earn additional income. The Fund receives cash collateral from the borrower in an amount not less than the market value of the loaned securities. The Fund will invest its cash collateral in State Street Institutional U.S. Government Money Market Fund (SAHXX), which is registered with the Securities and Exchange Commission (SEC) as an investment company. SAHXX invests substantially all of its assets in the State Street U.S. Government Money Market Portfolio. The Fund will receive the benefit of any gains and bear any losses generated by SAHXX with respect to the cash collateral.

The Fund has the right to recall loaned securities on demand. If a borrower fails to return loaned securities when due, then the lending agent is responsible and indemnifies the Fund for the lent securities. The lending agent uses the collateral received from the borrower to purchase replacement securities of the same issue, type, class and series of the loaned securities. If the value of the collateral is less than the purchase cost of replacement securities, the lending agent is responsible for satisfying the shortfall but only to the extent that the shortfall is not due to any decrease in the value of SAHXX.

Although the risk of loss on securities lent is mitigated by receiving collateral from the borrower and through lending agent indemnification, the Fund could experience a delay in recovering securities or could experience a lower than expected return if the borrower fails to return the securities on a timely basis. The Fund receives compensation for lending its securities by retaining a portion of the return on the investment of the collateral and compensation from fees earned from borrowers of the securities. Securities lending income received by the Fund is net of fees retained by the securities lending agent. Net income received from SAHXX is a component of securities lending income as recorded on the Statement of Operations.

Obligations to repay collateral received by the Fund are shown on the Statement of Assets and Liabilities as Payable upon return of securities loaned and are secured by the loaned securities. As of March 31, 2022, the Fund loaned securities valued at $11,111,831 and received $11,515,977 of cash collateral.

Repurchase Agreements

In managing short-term investments the Fund may from time to time enter into transactions in repurchase agreements. In a repurchase agreement, the Fund's custodian takes possession of the underlying collateral securities from the


25

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

counterparty, the market value of which is at least equal to the principal, including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the agreement, realization and/or retention of the collateral by the Fund may be delayed. The Fund may enter into repurchase transactions with any broker, dealer, registered clearing agency or bank. Repurchase agreement transactions are not counted for purposes of the limitations imposed on the Fund's investment in debt securities.

Distribution Policy

Pursuant to a Securities and Exchange Commission exemptive order, the Fund may make periodic distributions that include capital gains as frequently as 12 times in any one taxable year in respect of its common shares, and the Fund has implemented a managed distribution policy (the Policy) providing for quarterly distributions at a rate set by the Trustees. Under the current Policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Fund intends to use net realized capital gains when making quarterly distributions, if available, but the Policy would result in a return of capital to shareholders if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. If taxable income and net long-term realized gains exceed the amount required to be distributed under the Policy, the Fund will at a minimum make distributions necessary to comply with the requirements of the Internal Revenue Code. The Policy has been established by the Trustees and may be changed by them without shareholder approval. The Trustees regularly review the Policy and the frequency and rate of distribution considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions.

The Fund's policy is to declare quarterly distributions in stock. The distributions are automatically paid in newly-issued full shares of the Fund unless otherwise instructed by the shareholder. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts of the Fund's transfer agent who will have whole and fractional shares added to their accounts. The Fund's transfer agent delivers an election card and instructions to each registered shareholder in connection with each distribution. The number of shares issued will be determined by dividing the dollar amount of the distribution by the lower of net asset value or market price on the pricing date. If a shareholder elects to receive a distribution in cash, rather than in shares, the shareholder's relative ownership in the Fund will be reduced. The shares


26

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

reinvested will be valued at the lower of the net asset value or market price on the pricing date. Distributions in stock will not relieve shareholders of any federal, state or local income taxes that may be payable on such distributions. Additional distributions, if any, made to satisfy requirements of the Internal Revenue Code may be paid in stock, as described above, or in cash.

Share Repurchase Program

In March 2022, the Trustees approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July 14, 2023. Prior to this renewal, in March 2021, the Trustees approved the renewal of the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2022. The share repurchase program is intended to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the Fund's net asset value.

During the six months ended March 31, 2022, the Fund did not repurchase any shares through the repurchase program.

During the year ended September 30, 2021, the Fund did not repurchase any shares through the repurchase program.

Federal Taxes

It is the Fund's policy to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders substantially all of its taxable income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision is required.

As of March 31, 2022, the Fund had no uncertain tax positions that would require financial statement recognition or disclosure. The Fund's federal tax returns are subject to examination by the Internal Revenue Service for a period of three years.

Distributions

The Fund records all distributions to shareholders on the ex-dividend date. Such distributions are determined in conformity with income tax regulations, which may differ from GAAP. These differences include temporary and permanent differences from losses on wash sale transactions, passive foreign investment companies transactions, installment sale adjustments, distribution re-designations, foreign currency gains and losses, book to tax difference due to merger and ordinary loss netting to reduce short term capital gains.


27

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

Reclassifications are made to the Fund's capital accounts to reflect income and gains available for distribution under income tax regulations.

Commitments and Contingencies

Under the Fund's organizational documents, its officers and Trustees may be indemnified against certain liabilities and expenses arising out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.

Investor Support Services

The Fund has retained Destra Capital Advisors LLC (Destra) to provide investor support services in connection with the ongoing operation of the Fund. The Fund pays Destra a fee in an annual amount equal to 0.05% of the average aggregate daily value of the Fund's Managed Assets pursuant to the investor support services agreement.

New Accounting Pronouncement

In October 2020, the SEC adopted new regulations governing the use of derivatives by registered investment companies. Rule 18f-4 will impose limits on the amount of derivatives a fund could enter into, eliminate the asset segregation framework currently used by funds to comply with Section 18 of the 1940 Act, and require funds whose use of derivatives is more than a limited specified exposure to establish and maintain a derivatives risk management program and appoint a derivatives risk manager. While the new rule became effective February 19, 2021, funds will not be required to fully comply with the new rule until August 19, 2022. It is not currently clear what impact, if any, the new rule will have on the availability, liquidity or performance of derivatives. When fully implemented, the new rule may require changes in how a fund will use derivatives, may adversely affect a fund's performance and may increase costs related to a fund's use of derivatives.

(2)  Investment Advisory and Other Affiliated Fees

The Fund has entered into an Investment Advisory Agreement (the Advisory Agreement) with the Adviser. Pursuant to the terms of the Advisory Agreement, the Fund pays the Adviser a monthly fee at the rate when annualized of (i) 2.50% of the average net assets for the month of its venture capital and


28

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

other restricted securities up to 25% of net assets and (ii) for all other net assets, 0.98% of the average net assets up to $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets thereafter. The aggregate fee would not exceed a rate when annualized of 1.36%.

The Fund has entered into a Services Agreement (the Agreement) with the Adviser. Pursuant to the terms of the Agreement, the Fund reimburses the Adviser for certain services related to a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the six months ended March 31, 2022, these payments amounted to $72,076 and are included in the Other category of expenses in the Statement of Operations, together with insurance and other expenses incurred to unaffiliated entities. Expenses incurred pursuant to the Agreement as well as certain expenses paid for by the Adviser are allocated to the Fund in an equitable fashion as approved by the Trustees or officers of the Fund who are also officers of the Adviser.

The Fund pays compensation to Independent Trustees in the form of a retainer, attendance fees, and additional compensation to Board and Committee chairpersons. The Fund does not pay compensation directly to Trustees or officers of the Fund who are also officers of the Adviser.

(3)  Other Transactions with Affiliates

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the six months ended March 31, 2022 were as follows:

Affiliated Companies

   Beginning
Value as of
September 30,
2021		   Purchases at
Cost		   Proceeds
from Sales		   Net Realized
Gain/(Loss)
on sale of
Affiliated
Companies		   Change in
Unrealized
Appreciation/
Depreciation		   Ending Value
as of
March 31,
2022		  
Amphivena
Therapeutics		  

$

86

    

$

—

    

$

—

    

$

—

    

$

—

    

$

86

    
Arkuda
Therapeutics, Inc.		    

2,800,002

      

871,943

      

—

      

—

      

1,352,320

      

5,024,265

    
Curasen
Therapeutics, Inc.		    

7,000,000

      

1,414,141

      

—

      

—

      

—

      

8,414,141

    

Invetx, Inc.

    

3,450,000

      

2,070,000

      

—

      

—

      

1,366,344

      

6,886,344

    

Priothera Ltd.

    

1,081,123

*

    

2,946,771

      

—

      

—

      

(192,902

)

    

3,834,992

    
   

$

14,331,211

    

$

7,302,855

    

$

—

    

$

—

    

$

2,525,762

    

$

24,159,828

    


29

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

Affiliated Companies

   Shares as of
March 31,
2022		   Principal
Amount as of
March 31,
2022		   Dividend/
Interest
Income
from
Affiliated
Companies		   Capital Gain
Distributions
from Affiliated
Companies		  

Amphivena Therapeutics

    

1,155,962

    

$

—

    

$

—

    

$

—

    

Arkuda Therapeutics, Inc.

    

2,841,458

      

—

      

—

      

—

    

Curasen Therapeutics, Inc.

    

17,547,740

      

—

      

—

      

—

    

Invetx, Inc.

    

10,276,591

      

—

      

—

      

—

    

Priothera Ltd.

    

346,666

      

—

      

—

      

—

    

   

32,168,417

    

$

—

    

$

—

    

$

—

    

* Not an affiliate as of September 30, 2021.

(4)  Fair Value Measurements

The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

For the period ended March 31, 2022, the total amount of transfers between Level 3 and Level 1 was $322. The investment was transferred due to an initial public offering and the value is being supported by the market price.

The total amount of transfers between Level 3 and Level 2 was $4,079,999. The investment was transferred due to an initial public offering lockup period and the value is being supported by significant observable inputs. There were no other transfers between levels.


30

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

The following is a summary of the levels used as of March 31, 2022 to value the Fund's investments.

Assets at Value

  

Level 1

  

Level 2

  

Level 3

  

Total

  

Convertible Preferred

  

Biotechnology

  

$

—

    

$

—

    

$

44,781,747

    

$

44,781,747

    

Health Care Equipment & Supplies

    

—

      

—

      

1,423,015

      

1,423,015

    

Pharmaceuticals

    

—

      

—

      

25,114,132

      

25,114,132

    

Convertible Notes

  

Biotechnology

    

—

      

—

      

0

*

    

0

    

Common Stocks

  

Biotechnology

    

483,004,391

      

3,269,680

      

—

      

486,274,071

    

Health Care Equipment & Supplies

    

69,725,711

      

—

      

778,215

      

70,503,926

    

Health Care Providers & Services

    

68,272,478

      

78,578

      

57,444

      

68,408,500

    

Healthcare Services

    

18,247,094

      

—

      

—

      

18,247,094

    

Life Sciences Tools & Services

    

69,089,345

      

—

      

—

      

69,089,345

    

Medical Devices and Diagnostics

    

15,476,917

      

—

      

—

      

15,476,917

    

Pharmaceuticals

    

171,690,421

      

1,725

      

—

      

171,692,146

    

Special Purpose Acquisition Company

    

1,904,727

      

—

      

—

      

1,904,727

    

Exchange Traded Fund

    

5,931,541

      

—

      

—

      

5,931,541

    

Short-term Investments

    

11,515,977

      

23,495,000

      

—

      

35,010,977

    

Milestone Interests

  

Biotechnology

    

—

      

—

      

1,737,827

      

1,737,827

    

Health Care Equipment & Supplies

    

—

      

—

      

1,982

      

1,982

    

Pharmaceuticals

    

—

      

—

      

7,958,509

      

7,958,509

    

Other Assets

    

—

      

—

      

5,166

      

5,166

    

Total

  

$

914,858,602

    

$

26,844,983

    

$

81,858,037

    

$

1,023,561,622

    

* Represents security valued at zero.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

Investments in
Securities		   Balance as of
September 30,
2021		   Net realized
gain (loss) and
change in
unrealized
appreciation
(depreciation)		   Cost of
purchases
and
conversions		   Proceeds
from
sales and
conversions		   Net
transfers
in
(out of)
Level 3		   Balance
as of
March 31,
2022		  

Convertible Preferred

  

Biotechnology

  

$

31,989,201

    

$

1,877,255

    

$

14,995,290

    

$

0

    

($

4,079,999

)

  

$

44,781,747

    
Health Care
Equipment &
Supplies		    

1,423,015

      

—

      

—

      

—

      

—

      

1,423,015

    

Pharmaceuticals

    

20,599,995

      

(3,156

)

    

4,517,293

      

—

      

—

      

25,114,132

    

Convertible Notes

  

Biotechnology

    

0

      

—

      

—

      

—

      

—

      

0

    


31

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

Investments in
Securities		   Balance as of
September 30,
2021		   Net realized
gain (loss) and
change in
unrealized
appreciation
(depreciation)		   Cost of
purchases
and
conversions		   Proceeds
from
sales and
conversions		   Net
transfers
in
(out of)
Level 3		   Balance
as of
March 31,
2022		  

Common Stocks

  

Biotechnology

  

$

322

    

$

—

    

$

—

    

$

—

    

($

322

)

  

$

—

    
Health Care
Equipment &
Supplies		    

1,768,200

      

(989,985

)

    

—

      

—

      

—

      

778,215

    
Health Care
Providers &
Services		    

139,911

      

(60,096

)

    

—

      

(22,371

)

    

—

      

57,444

    

Milestone Interests

  

Biotechnology

    

1,758,375

      

(20,548

)

    

—

      

—

      

—

      

1,737,827

    
Health Care
Equipment &
Supplies		    

1,982

      

—

      

—

      

—

      

—

      

1,982

    

Pharmaceuticals

    

9,289,198

      

(1,330,689

)

    

—

      

—

      

—

      

7,958,509

    

Other Assets

    

15,966

      

—

      

—

      

(10,800

)

    

—

      

5,166

    
   

$

66,986,165

    

($

527,219

)

  

$

19,512,583

    

($

33,171

)

  

($

4,080,321

)

  

$

81,858,037

    
Net change in unrealized appreciation (depreciation) from
investments still held as of March 31, 2022		  

($

527,219

)

  

The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.

    Fair Value at
March 31,
2022		  

Valuation Technique

  

Unobservable Input

   Range
(Weighted Average)		  

Common Stock

 

$

778,215

    

Income approach,

 

(a)

  

N/A

 
    57,444
 		   Probability adjusted
value		   Probability of events
Timing of events		   50.00% (50.00%)
1.00-2.00 (1.50) years		  
Convertible Preferred
 		   43,470,235
27,848,659		   Market approach
Recent transactions		   (a)
(b) 		  N/A
N/A 		 
Milestones Interests
 		   9,698,318
 		   Probability adjusted
value		   Probability of events
Timing of events		   0.00%-100.00% (73.03%)
0.50-14.25 (3.88) years		  
Other Assets
 		    

5,166

     Probability adjusted
value		   Probability of events
Timing of events		   20.00%-95.00% (23.95%)
0.25-6.00 (0.55) years		  
   

$

81,858,037

                

(a)  There is no quantitative information to provide as this method of measure is investment specific.

(b)  The valuation technique used as a basis to approximate fair value of these investments is based upon subsequent financing rounds.


32

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

(5)  Private Companies and Other Restricted Securities

The Fund may invest in private companies and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represented 8% of the Fund's net assets at March 31, 2022.

At March 31, 2022, the Fund had a commitment of $3,342,519 relating to additional investments in four private companies.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at March 31, 2022. The Fund on its own does not have the right to demand that such securities be registered.

Security (#)

   Acquisition
Date		  

Cost

   Carrying Value
per Unit		  

Value

  

Afferent Milestone Interest

  

07/27/16

  

$

377,701

    

$

295,365.00

    

$

295,365

    

Amphivena Therapeutics, Inc.

  

Series B Cvt. Pfd

  

07/17/17

    

4,902,917

      

0.00

††

    

33

    

Series C Cvt. Pfd

  

12/10/18

    

1,887,420

      

0.00

††

    

53

    

Cvt. Note

  

08/25/21

    

303,324

      

0.00

      

0

    

Arbor Biotechnologies Series B Cvt. Pfd

  

10/29/21

    

1,367,052

      

16.57

      

1,359,999

    

Aristea Therapeutics, Inc. Series B Cvt. Pfd

  

07/27/21

    

3,399,996

      

5.51

      

3,399,996

    

Arkuda Therapeutics, Inc.

  

Series A Cvt. Pfd

  

05/16/19, 04/02/20, 07/15/21

    

5,608,507

      

1.77

      

4,162,222

    

Series B Cvt. Pfd

  

01/24/22

    

863,441

      

1.77

      

862,043

    

Biotheryx, Inc. Series E Cvt. Pfd

  

05/19/21

    

6,809,590

      

5.25

      

6,800,000

    

Cercacor Laboratories, Inc. Common

  

03/31/98†

    

0

      

4.86

      

778,215

    
Curasen Therapeutics, Inc.
Series A Cvt. Pfd		  

09/18/18, 01/07/20, 10/21/21

    

8,414,141

      

0.48

      

8,414,141

    

Dynacure Series C Cvt. Pfd

  

04/21/20, 10/28/20

    

5,611,822

      

4.59

      

2,766,370

    

Endeavor Biomedicines, Inc. Series B Cvt. Pfd

  

01/21/22

    

3,103,019

      

4.72

      

3,099,996

    

Ethismos Research Milestone Interest

  

10/31/17

    

0

      

0.00

      

0

    

HiberCell, Inc. Series B Cvt. Pfd

  

05/05/21

    

3,406,945

      

1.23

      

3,399,999

    

Hotspot Therapeutics, Inc.

  

Series B Cvt. Pfd

  

04/22/20, 06/17/21

    

6,905,056

      

3.24

      

9,317,587

    

Series C Cvt. Pfd

  

11/15/21

    

2,050,638

      

3.24

      

2,049,526

    

ImmuneID, Inc. Series A Cvt. Pfd

  

04/28/21

    

2,044,520

      

2.00

      

2,040,000

    

Impact Biomedicines Milestone Interest

  

07/20/10

    

0

      

1,765,258.00

      

1,765,258

    

InnovaCare, Inc. Escrow Shares Common

  

12/21/12†

    

73,738

      

0.26

      

57,444

    

Invetx, Inc.

  

Series A Cvt. Pfd

  

08/06/20

    

3,450,000

      

0.67

      

4,816,344

    

Series B Cvt. Pfd

  

03/28/22

    

2,070,000

      

0.67

      

2,070,000

    


33

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2022

(continued)

Security (#)

   Acquisition
Date		  

Cost

   Carrying Value
per Unit		  

Value

  

IO Light Holdings, Inc. Series A2 Cvt. Pfd

  

04/30/20†

  

$

1,394,759

    

$

3.38

    

$

1,423,015

    
Moonlake Immunotherapeutics AG Class A
Common		  

03/30/22

    

2,058,000

      

9.00

      

1,852,200

    

Neurovance Milestone Interest

  

03/20/17

    

4,917,880

      

5,897,886.00

      

5,897,886

    

Oculis SA

  

Series B2 Cvt. Pfd

  

01/16/19

    

2,335,687

      

10.64

      

2,952,004

    

Series C Cvt. Pfd

  

04/07/21

    

801,905

      

10.64

      

801,905

    

Parthenon Therapeutics, Inc. Series A Cvt. Pfd

  

08/12/21

    

2,092,307

      

3.96

      

2,092,307

    

Priothera Ltd. Series A Cvt. Pfd

  

10/07/20,10/19/21

    

4,044,974

      

11.06

      

3,834,992

    

Pyxis Oncology, Inc. Common

  

03/05/21

    

4,085,725

      

3.64

      

1,417,480

    

Quell Therapeutics, Series B Cvt. Pfd

  

11/29/21

    

2,955,249

      

1.89

      

2,936,363

    

Rainier Therapeutics Milestone Interest

  

09/28/21

    

395,493

      

421,161.00

      

421,161

    

ReCode Therapeutics Series B Cvt. Pfd

  

10/12/21

    

2,728,580

      

9.23

      

2,719,999

    

Therachon Milestone Interest

  

07/01/19

    

2,362,765

      

1,316,666.00

      

1,316,666

    

Therox Milestone Interest

  

06/18/19

    

7,611

      

1,982.00

      

1,982

    
       

$

92,830,762

        

$

85,122,551

    

  (#)  See Schedule of Investments and corresponding footnotes for more information on each issuer.

  †  Carrying Interest received as part of a corporate action for a previously owned security.

  ††  Carrying value per unit is greater than $0.00 but less than $0.01


34

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

The Investment Advisory Agreement (the Advisory Agreement) between the Fund and the Adviser continues in effect so long as its continuance is approved at least annually by (i) the Trustees of the Fund and (ii) a majority of the Trustees of the Fund who are not interested persons (the Independent Trustees), by vote cast in person at a meeting called for the purpose of voting on such approval.

After considering the matter in a meeting held on March 17, 2022, the Board, and the Independent Trustees voting separately, determined that the terms of the Advisory Agreement are fair and reasonable and approved the continuance of the Advisory Agreement as being in the best interests of the Fund and its shareholders. In making its determination, the Board considered materials that were specifically prepared by the Adviser and by an independent data provider at the request of the Board and Fund counsel for purposes of the contract review process, including comparisons of (i) the Fund's performance both directly and on a risk adjusted basis to a benchmark, the NASDAQ Biotechnology Index® (NBI), and to a peer universe of other investment companies, (ii) the Fund's expenses and expense ratios to those of a peer group of other investment companies, and (iii) the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers. The Trustees took into account that substantially all of the Adviser's business consists of providing investment management services to Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund and the Adviser does not derive any significant benefit from its relationship with the Fund other than receipt of advisory fees pursuant to the Advisory Agreement, market research and potential marketing exposure for the Adviser. The Board also received and reviewed information throughout the year about the portfolio performance, the investment strategy, the portfolio management team and various fees and expenses of the Fund. In their deliberations, the Independent Trustees had the opportunity to meet privately without representatives of the Adviser present and were represented throughout the process by counsel to the Independent Trustees and the Fund.

In approving the Advisory Agreement, the Board considered, among other things, the nature, extent, and quality of the services to be provided by the Adviser, the investment performance of the Fund and the Adviser, the costs of services provided and profits realized by the Adviser and its affiliates, and whether fee levels reflect any economies of scale for the benefit of Fund shareholders and the extent to which economies of scale would be realized as the Fund grows. The Board reviewed information about the foregoing factors and


35

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

(continued)

considered changes, if any, in such information since its previous approval. The Board also evaluated the financial strength of the Adviser and the capability of the personnel of the Adviser, specifically the strength and background of its investment analysts. Fund counsel provided the Board with the statutory and regulatory requirements for approval and disclosure of investment advisory agreements. The Board, including the Independent Trustees, evaluated all of the foregoing and, considering all factors together, determined in the exercise of its business judgment that the continuance of the Advisory Agreement is in the best interests of the Fund and its shareholders. The following provides more detail on certain factors considered by the Trustees and the Board's conclusions with respect to each such factor.

The nature, extent and quality of the services to be provided by the Adviser. On a regular basis the Board considers the roles and responsibilities of the Adviser as a whole, along with specific portfolio management, support and trading functions the Adviser provides to the Fund. The Trustees considered the nature, extent and quality of the services provided by the Adviser to the Fund. The Trustees continue to be satisfied with the quality and value of the investment advisory services provided to the Fund by the Adviser, and, in particular, the management style and discipline followed by the Adviser and the quality of the Adviser's research, trading, portfolio management, compliance and administrative personnel. The Trustees also took into account the Adviser's significant investment in its business through the addition of portfolio management and administrative staff over the last several years and the Adviser's commitment to continue to build out its infrastructure as future circumstances require.

The investment performance of the Fund and the Adviser. On a regular basis the Board reviews performance information of the Fund and discusses the Fund's investment strategy with the Adviser. The Trustees reviewed performance information for the Fund for the past one-, three-, five- and ten-year periods ended December 31, 2021, as compared to its benchmark, the NBI, and a peer universe of other investment companies identified by an independent service provider engaged by the Independent Trustees. The Trustees noted that the performance information reviewed reflects a view of the Fund's performance only as of a certain date, and that the results might be significantly different if a different date was selected to generate the performance information. Additionally, the Trustees recognized that longer periods of performance for the Fund may be adversely and disproportionately affected by significant underperformance in one more recent period, and that such underperformance may be caused by a small number of investment decisions or positions.


36

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

(continued)

Unlike many other broader-based healthcare indices, the NBI contains high levels of biotechnology-based companies. Over time, this index has demonstrated higher returns, but has also demonstrated higher price volatility than the broad S&P 500® Index. The Adviser seeks to operate the Fund at a biotechnology exposure level that is higher than many other indices and Funds but at a level that is below that of the NBI. The Adviser also seeks to operate the Fund at lower volatility than that of the NBI. In the current reporting period, the Adviser sought to do so by limiting exposure to biotechnology relative to the NBI and also by maintaining a higher exposure to large healthcare companies (which exhibit relatively lower volatility) than is present in the NBI and lower exposure to small and mid-capitalization biotechnology companies than is present in the NBI.

The Trustees noted the Fund's strong absolute performance as of December 31, 2021 for the three-, five- and ten-year periods ended December 31, 2021. In particular, the Trustees noted that on a net asset value basis, the Fund returned 2.60% for the one-year period and had annualized returns of 15.22% for the three-year period, 10.60% for the five-year period, and 13.89% for the ten-year period. The Trustees also noted that on a net asset value basis, as of December 31, 2021, the Fund outperformed the NBI for the one-year period and underperformed the NBI for the three-, five- and ten-year periods. The Trustees also noted that for all evaluation periods ended December 31, 2021, the Fund exhibited lower volatility than the NBI and outperformed the NBI on a risk adjusted basis. The Trustees noted that as of December 31, 2021, the Fund underperformed the peer universe average for the one-, three-, five- and ten-year periods.

In considering the Fund's relative performance, the Trustees recognized that the Fund's unique strategy presents challenges when comparing the Fund's performance to a benchmark or group of comparable funds. In particular, the Trustees observed that the Fund's strategy has historically included a lower biotechnology allocation compared to the NBI and a higher biotechnology allocation compared to many other healthcare indices and to many of the other funds in the peer universe. The Trustees noted that, as a result, all other things being equal, in periods when biotechnology performs relatively well, the Fund might be expected to underperform the NBI (and/or the peer universe) and vice versa. Additionally, the Trustees noted that unlike the NBI and most of the peer universe, the Fund often maintains a meaningful allocation to venture and restricted securities. In light of these differences, the Trustees recognized the more limited usefulness of these performance comparisons for the Fund.


37

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

(continued)

The Trustees concluded they continue to be satisfied with the investment performance of the Fund and the Adviser.

The costs of services to be provided and profits to be realized by the Adviser from its relationship with the Fund. The Trustees considered the various services provided by the Adviser to the Fund and reviewed comparative information regarding the expenses and expense ratios of the Fund and a peer group of other investment companies identified by an independent service provider engaged by the Independent Trustees. The Trustees noted that the Adviser's fees are within the range of fees presented in the comparative information and noted that the Fund often maintains a meaningful allocation to venture and restricted securities, a portfolio management service that can warrant higher management fees than those charged by the Adviser to the Fund. The Trustees also considered financial information provided by the Adviser, including financial statements of the Adviser and a comparison of the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers.

The Trustees noted that the fees charged by the Adviser are within a reasonable range of fees as compared to fees charged by other investment advisers for similar services, and the services provided by the Adviser and the amounts paid under the Advisory Agreement are at least comparable to the services rendered and fees charged by others for similar services to warrant a finding that fees to be paid by the Fund are fair. Based on the information provided to and evaluated by the Trustees, the Trustees concluded that the fees charged by the Adviser are fair and reasonable in light of the quality and nature of the services provided by the Adviser and that the profitability of the Adviser's relationship with the Fund has not been excessive.

Whether fee levels reflect economies of scale and the extent to which economies of scale would be realized as the Fund grows. The Trustees considered the advisory fee schedule in the Advisory Agreement and noted that it provides for breakpoints that would reduce the effective fee to the extent the Fund's net assets should increase, allowing the Fund to share in the benefits of any economies of scale that would inure to the Adviser as the Fund's assets increase. Given the closed-end structure of the Fund, its current asset size, and the fact that any economies of scale are modest at current Fund asset levels, the Trustees determined that the Fund's advisory fee schedule is satisfactory and fair.


38

TEKLA HEALTHCARE INVESTORS

PRIVACY NOTICE: If you are a registered shareholder of the Fund, the Fund and Tekla Capital Management LLC, the Fund's investment adviser, may receive nonpublic personal information about you from the information collected by the transfer agent from your transactions in Fund shares. Any nonpublic personal information is not disclosed to third parties, except as permitted or required by law. In connection with servicing your account and effecting transactions, the information received may be shared with the investment adviser and non-affiliates, including transfer agents, custodians or other service companies. Access to your nonpublic personal information is restricted to employees who need to know that information to provide products or services to you. To maintain the security of your nonpublic personal information, physical, electronic, and procedural safeguards are in place that comply with federal standards. The policies and practices described above apply to both current and former shareholders.

If your Fund shares are held in "street name" at a bank or brokerage, we do not have access to your personal information and you should refer to your bank's or broker's privacy policies for a statement of the treatment of your personal information.

FOR MORE INFORMATION: A description of the Fund's proxy voting policies and procedures and information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available (i) without charge, upon request by calling 1-800-451-2597; (ii) by writing to Tekla Capital Management LLC at 100 Federal Street, 19th Floor, Boston, MA 02110; (iii) on the Fund's website at www.teklacap.com; and (iv) on the SEC's website at www.sec.gov.

The Fund's complete Schedule of Investments for the first and third quarters of its fiscal year will be filed with the SEC on Form N-PORT. This Schedule of Investments will also be available on the Fund's website at www.teklacap.com or the SEC's website at www.sec.gov.

You can find information regarding the Fund at the Fund's website, www.teklacap.com. The Fund regularly posts information to its website, including information regarding daily share pricing, distributions, press releases and links to the Fund's SEC filings. The Fund currently publishes and distributes quarterly fact cards, which include performance, portfolio holdings and sector information for each fiscal quarter. These fact cards will be available on the Fund's website and by request from the Fund's marketing and investor support services agent, Destra Capital Advisors LLC, at 1-877-855-3434.


39

TEKLA HEALTHCARE INVESTORS

DISTRIBUTION POLICY: The Fund has a managed distribution policy as described in the Notes to Financial Statements. For more information contact your financial adviser.

SHARE REPURCHASE PROGRAM: In March 2022, the Trustees reauthorized the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July 14, 2023.

PORTFOLIO MANAGEMENT: Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy Gasperoni, M.B.A., Ph.D., Ashton L. Wilson, Loretta Tse, Ph.D., Christopher Abbott, Robert Benson, Richard Goss, Jack Liu, M.B.A., Ph.D., Christopher Seitz, M.B.A. and Kelly Girskis, Ph.D. are members of a team that analyzes investments on behalf of the Fund. Dr. Omstead exercises ultimate decision making authority with respect to investments.

HOUSEHOLDING: A number of banks, brokers and financial advisers have instituted "householding". Under this practice, which has been approved by the SEC, only one copy of shareholder documents may be delivered to multiple shareholders who share the same address and satisfy other conditions. Householding is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. If you do not want the mailing of your shareholder documents to be combined with those of other members of your household, please contact your bank, broker or financial adviser.


40

TEKLA HEALTHCARE INVESTORS

New York Stock Exchange Symbol: HQH
NAV Symbol: XHQHX

100 Federal Street, 19th Floor
Boston, Massachusetts 02110
(617) 772-8500
www.teklacap.com

Officers

Daniel R. Omstead, Ph.D., President
Laura Woodward, CPA, Chief Compliance Officer,
Secretary and Treasurer

Trustees

Jeffrey A. Bailey
Kathleen L. Goetz
Rakesh K. Jain, Ph.D.
Thomas M. Kent, CPA
Daniel R. Omstead, Ph.D.
Oleg M. Pohotsky, M.B.A., J.D.
William S. Reardon, M.B.A.

Investment Adviser

Tekla Capital Management LLC

Administrator & Custodian

State Street Bank and Trust Company

Transfer Agent

Computershare, Inc.

Legal Counsel

Dechert LLP

Shareholders with questions regarding share transfers may call

1-800-426-5523

Daily net asset value may be obtained from
our website (www.teklacap.com) or by calling

617-772-8500

 

ITEM 2. CODE OF ETHICS.

 

Not applicable to this semi-annual filing.

 

ITEM 3. AUDIT COMMITTEE FINANCIAL EXPERT.

 

Not applicable to this semi-annual filing.

 

ITEM 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

Not applicable to this semi-annual filing.

 

ITEM 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.

 

Not applicable to this semi-annual filing.

 

ITEM 6. INVESTMENTS.

 

The Registrant’s Schedule of Investments is included as part of the Report to Shareholders filed under Item 1 of this form.

 

ITEM 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.

 

Not applicable to this semi-annual filing.

 

 

 

 

ITEM 8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES

 

Not applicable to this semi-annual filing.

 

ITEM 9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS.

 

Period  (a) Total No.
of Shares
Purchased (1)		   (b) Average
Price Paid per
Share		   (c) Total No.
of Shares
Purchased as
Part of
Publicly
Announced Plans
or Programs		   (d) Maximum No.
of Shares that
May Yet Be
Purchased Under
the Plans or
Programs		 
Month #1 (Oct. 1, 2021—Oct. 31, 2021)   —  —    —    5,404,055 
Month #2 (Nov. 1, 2021— Nov. 30, 2021)   —    —    —    5,404,055 
Month #3 (Dec. 1, 2021 — Dec. 31, 2021)   —    —    —    5,404,055 
Month #4 (Jan. 1, 2022 — Jan. 31, 2022)   —    —    —    5,404,055 
Month #5 (Feb. 1, 2022— Feb. 28, 2022)   —    —    —    5,404,055 
Month #6 (Mar. 1, 2022 — Mar. 31, 2022)   —   —    —    5,404,055 
Total   —   —    —      

 

(1)On June 30, 2011, the share repurchase program was announced, which has been subsequently reviewed and approved by the Board of Trustees. On March 18, 2021 the share repurchase program was renewed, allowing the Registrant to repurchase up to 12% of its outstanding shares for a one year period ending July 14, 2022. On March 17, 2022, the Trustees approved the renewal of the repurchase program to allow the Registrant to repurchase up to 12% of its outstanding shares in the open market for a one year period ending July 14, 2023.

 

ITEM 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

There have been no material changes to the procedures by which the shareholders may recommend nominees to the Registrant’s Board of Trustees, where those changes were implemented after the Registrant last provided disclosure in response to the requirements of Item 7(d)(2)(ii)(G) of Schedule 14A, or this Item.

 

ITEM 11. CONTROLS AND PROCEDURES.

 

(a)In the opinion of the principal executive officer and principal financial officer, based on their evaluation which took place within 90 days of this filing, the Registrant’s disclosure controls and procedures are adequately designed and are operating effectively to ensure (i) that material information relating to the Registrant, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which this report is being prepared; and (ii) that information required to be disclosed by the registrant on Form N-CSR is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

 

(b)There were no changes in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal half-year that have materially affected or that are reasonably likely to materially affect the Registrant’s internal control.

 

 

 

 

Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.

 

Not applicable to this semi-annual filing. 

 

ITEM 13. EXHIBITS

 

(a)(1) Code of Ethics - Not applicable to this semi-annual filing.

 

(a)(2) Separate certifications of the Principal Executive and Financial Officers as required by Rule 30a-2(a) under the 1940Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 1 and 2).

 

(a)(3) Notices to Fund’s shareholders in accordance with Investment Company Act Section 19(a) and Rule 19a-1 (Exhibit 3).

 

(b) Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 4).

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant) TEKLA HEALTHCARE INVESTORS  
     
By (Signature and Title)* /s/ Daniel R. Omstead  
  Daniel R. Omstead, President  

 

Date: 6/3/22  

 

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By (Signature and Title)* /s/ Laura Woodward  
  Laura Woodward, Treasurer  

 

Date: 6/3/22  

 

 

* Print the name and title of each signing officer under his or her signature.

 

 

 EX-99.CERT 2 tm228075d1_ex99cert.htm EXHIBIT 99.CERT

 

EXHIBIT 99.CERT

 

EXHIBIT 1: CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Daniel R. Omstead, certify that:

 

1.I have reviewed this report on Form N-CSR of TEKLA HEALTHCARE INVESTORS;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the Registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: 6/3/22   /s/ Daniel R. Omstead
      Name: Daniel R. Omstead
      Title: President

 

 

 

 

EXHIBIT 2: CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Laura Woodward, certify that:

 

1.I have reviewed this report on Form N-CSR of TEKLA HEALTHCARE INVESTORS;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the Registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: 6/3/22   /s/ Laura Woodward
      Name: Laura Woodward
      Title: Treasurer

 

 

 

 EX-99.SECTION19(A) 3 tm228075d1_ex99section19a.htm EXHIBIT 99.SECTION19(A)

Exhibit 99.Section 19(a)

 

EXHIBIT 3: SECTION 19(a) NOTICE TO FUND’S SHAREHOLDERS

 

TEKLA HEALTHCARE INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: December 31, 2021

 

Distribution Amount Per Common Share: $0.51

 

The following table sets forth the estimated amounts of the current distribution, paid December 31, 2021, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with `yield' or `income'. All amounts are expressed per common share.

 

                      Percentage   
          Percentage           Breakdown of the  
          Breakdown     Total Cumulative     Total Cumulative  
    Current     of Current     Distributions for the     Distributions for the  
    Distribution     Distribution     Fiscal Year to Date1     Fiscal Year to Date1  
Net Investment Income   $ 0.0000       0 %   $ 0.0000       0 %
Net Realized ST Cap Gains   $ 0.1173       23 %   $ 0.1173       23 %
Net Realized LT Cap Gains   $ 0.0000       0 %   $ 0.0000       0 %
Return of Capital or Other Capital Source   $ 0.3927       77 %   $ 0.3927       77 %
TOTAL (per common share):   $ 0.5100       100 %   $ 0.5100       100 %

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period October 31, 2016 through October 31, 2021   11.61%
Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2021   8.03%
Cumulative total return at NAV for the fiscal year, through October 31, 20212   -0.20%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of October 31, 20211   2.01%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $267,547,292, of which $299,903,741 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2021.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2021 through October 31, 2021.

 

Tekla Healthcare Investors

CUSIP: 87911J103

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03K6EC     002CSNC79C

 

 

 

 

TEKLA HEALTHCARE INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: March 31, 2022

 

Distribution Amount Per Common Share: $0.48

 

The following table sets forth the estimated amounts of the current distribution, paid March 31, 2022, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with `yield' or `income'. All amounts are expressed per common share.

 

               Percentage 
       Percentage       Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0000    0%  $0.1173    12%
Net Realized LT Cap Gains  $0.2870    60%  $0.2870    29%
Return of Capital or Other Capital Source  $0.1930    40%  $0.5857    59%
TOTAL (per common share):  $0.4800    100%  $0.9900    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period January 31, 2017 through January 31, 2022   7.71%
Annualized current distribution rate expressed as a percentage of NAV as of January 31, 2022   8.67%
Cumulative total return at NAV for the fiscal year, through January 31, 20222   -11.24%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of January 31, 20221   4.47%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $196,748,005 of which $183,655,454 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2021.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2021 through January 31, 2022.

 

Tekla Healthcare Investors

CUSIP: 87911J103

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03MCEB     002CSNCB9D

 

 

 EX-99.906 CERT 4 tm228075d1_ex99-906cert.htm EXHIBIT 99.906 CERT

 

Exhibit 99.906CERT

 

EXHIBIT 4: CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of TEKLA HEALTHCARE INVESTORS, do hereby certify, to such officer’s knowledge, that the report on Form N-CSR of TEKLA HEALTHCARE INVESTORS for the period ended March 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and information contained in the Form N-CSR fairly presents, in all material respects, the financial condition and results of operations of TEKLA HEALTHCARE INVESTORS for the stated period.

 

Dated: 6/3/22    
       
  /s/ Daniel R. Omstead   /s/ Laura Woodward
  Name: Daniel R. Omstead   Name: Laura Woodward
  Title: President   Title: Treasurer

 

A signed original of this written statement required by Section 906 has been provided to TEKLA HEALTHCARE INVESTORS and will be retained by TEKLA HEALTHCARE INVESTORS and furnished to the SEC or its staff upon request. This statement accompanies this report on Form N-CSR pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 GRAPHIC 5 j2280752_aa001.jpg GRAPHIC begin 644 j2280752_aa001.jpg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j2280752_ba002.jpg GRAPHIC begin 644 j2280752_ba002.jpg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end GRAPHIC 7 j2280752_ba003.jpg GRAPHIC begin 644 j2280752_ba003.jpg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end GRAPHIC 8 j2280752_ba004.jpg GRAPHIC begin 644 j2280752_ba004.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ H@!T P$1 (1 0,1 ?_$ :( & @,! M <(!@4$"0,* @$ "P$ 8# 0$! !@4$ P<"" $) H+ M$ " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R( "#$403(C%0E10A9A)#,7 M4G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8 MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R'EZ>W MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FINM^0>+"Y^@_J;6L?;WV]-=/,.- M8Z<(\6Y4G3_AS^?\ M>OZ^_5ZW0]2(\<."P!M_4?[P?Z^_5Z]0]9I:2G0ZW:.)+6O<)<\_2Y O;WZI MZ]2G3;)+C%T_[D:(7("@U4 )_%O5(+G_ ]^Z]U/CI[J.;AA<,+$$?7_ &(L M?K[]7KW4>6G&HG1R/Z#_ &P]^ZUU@\-K\7L?^-GCW[KW7 P*?[)'_&^.+C_' MWOKW7!Z=2+#CC\CZ?C_;>_5Z]U#:E^IM<7_Q_P!Y^OY]^QU[I6?;C^X.G3Q_ M?#5^G_JRV_WOWKS_ "ZWY=)J"A/UT6'/!!Y^I/\ O/O?6NG>"A)(X) XTKR# MQ]#8_47]ZKUOI_IL?H4,4M]?K]+7_K;\^_=>X<.IGVD5BQ4'C@6'U^O']??J M=>KUS6G!%E7GZ'@BW^\?\:]^Z]7IKR5128V)I)W1G 5EI493/)CG2>.RV;[:X%]/!Y?Z;Z&WX?\ SC[,ZVS<>RN^LM7YG8\KBCHL]DV> MOR&,JI9E2E<5DP\IHO&%#QE]$0/I1-)+49*_;U<-3[.KP=@]H=?]G"H3:.X\ M9DZRFC6HFHH*NG>J:BD5&BR$$22.:C'S"5=,T>I/4 2"?;14CCU8$'H16H!^ M%O\ 4'ZGZ?[Q^/>NMXZCFBTWNFJU_J.?>L]>H.NWH4(_S?T%K$&]OK]??L]> MQU!DH K747%_\?S^/I>WOU>M4Z5?VJ_W+TZ.?[SZK6'U_A5OI:WTX]^_%UNA MITWP8\GEE Y/''^\ <^_4Z]4>73Q3XZP^@YY^GX_/X]^J!UKIQ6B"VL+_P!1 M]5/7NLGV0-KQB]P;GZ#C_;W]ZJ>O=(;L_?.WNK-G9+=N?ETQTRK3X^BB M*-6YC,5%TQV)Q\,CQ_<5E;/956X %V)"@D64$FG7C@5/55F4[FKLWN>6FW-N M&WPN,=-UKQZ8= MZ]BR[DI1B,.DF-PT$)IU$,J+-/'TV* MQ0I$A,0 1"OI1(]1=0&#:65KL%MS[MUKH'>Q.NZ"NHYY::FIR9E=7143U K) MJ60$:9!(&^C<&_U]^ZUT2[;O9/8WQ4[1VMN/:%?5PX_^+-+CXJN5WH(I) 6K MMLU].S"2KQ>2BN80I+ .W *#54C%/+JX-?MZVR^FNS-M]X]7;,[4VB^K"[QP ML&2BIW=&FQ]8K24N5Q%64)3[W$92GFII;<>2(VX]IS530]6Z$&6E-CZ/I_7_ M 'DM]1Q3GGC_?7Y_%[^]]:ZX?:$WN!]3:W]/Q]?S[]UOI0?;_ ._4 MT:>?X_>W-_\ BW6O[U^+\NO>7Y]=P4E@+B_T^MR?Z?TYO[T37KW3FE*0 Q 4 M?4$_G_6'Y_WOWZG5J>O7?C>]@I)_WGW[[.O<.'4J%!<+(C:B0 0">2> 0 3[ M]Y=;ZJM^<&XLB_8RO62&/;?4^VX,Q14!=$BJ]UY:!JM*BJ]+L7>*6BAA TO$ M0SDZ6LST?#[>FG.?D.JV>NZM\@:W(.YFJ![]UNG46JP:5-.P8!F (/U((*FUP#O4Z)+W_UO%N3#9;$Q 1UG MACK\54II66ERU#*TU!+'(5+Q+)->-R.0CM8CZ^_$5'7@:'JS'^4!OU:G8.\. MI:K5$M&:#M/;=+QX\=2;O H-VX"%!Z::'$;JQYG\?J.O(.P(0HH8D7@>G%H3 M3JXR:ET?6Q'XXN#_ (<^VJ=6(Z;'@"O:R$6#?6WU)^GUX-O?NM==7YM_P K>_9KUNF.G""D ](4,>3<@&W^N?J M/>B?3J_6;[1G(!4B]P20+ ?Z]O\ >/>]77NI<6+'!+-Q?](L.?Z_6_OU>JUZ M>J>@5/4$%^>;<_C\VU>]<./7LGCUKJ?S+MWR87??8.(BF)J,EN3%05+%QV:66D165@Q2)*F- OT#Q?3T^U4?P@]--\5.BG=/5318"CJ))02D3O(2XTZ; MZY"?[7'Y_''N_5.C,8;-4F2*+#74Q922Z1R)J%B/PNHKR?\ 7]^X=;Z7].JS M1H;KI!%GU6"@V)-A_C_L1[J>MXZ;,MEL#@8C-D^/7L=%S[0JXTJ2Z,KI.J^*2,JRO'(&L5T\,&_Q%N/>^J]#W_+ MMQT6 [_ZP?$%BN\-E=M4&4BB\:I#BJ7*25E,T\8.K1%7;4HQJ55NTZGZ$CVW M)\'3B<:]7^5%(Z%M7*D\$@D?X6-K?CVP#T[TTS489M2VN !8\?ZX!%OH??J= M:(ZS0TPXUW((_I:W^\#WZG7@.G[[6/\ @VC4;?Q'7]1?_@-:W^VY_K[U7/5N MGF.FX %@/R+7/]?^)]ZIU2I/4^&CU?V>+BYL;7_PXY]^P.MT]>G6"B6UV XX M'U_V]O?J]6ZG+"@_'_%/>NO=:FG\U3;NY=K=[]DPRR4^2QU1E\!N:E:"J<5M M-2;OEK,MCY:FED5;BEG.0H1I+#PTRL.3I56AJ@Z984;H@\F[]Q;:P^&:MH,I M7X>N$3)C\) DF6R,DDH@AI(#4-'211%SJ>61EA0"Y:^GW?/5: ],.T-Z=N[T MK]PYW96W-_[(Q.SLM#MR3&=@T6+:3)2M#453YW;F6Q%/15.4QM*\"05$H\L" M>:,ZV +1ZSUN@ZL2V1OG-;RZ=>N@G-)N'(8EHEJG:4K099U:'2_@;R@15(NQ M7U6_3S;WOJO#'5;V>V;\G,+V+B8ABI=^X?<"Y&7*YZMW'-08[!3T]? ]/#D( M==5E 9:6)FAJ*$S!698S&I>317-<<.K56G1QZ/&[OJ-N0Y;P(^GOU3UNO7):!%/T)!OPU M[C_6L!>WO53UJHZ]LW@:65_3I66#&TK:3>PUG_56*B+X>FGX]%NZMR&T=T8&@QN< MH[S,(I::>-BU7%XA: !WLX14&OZD:C8\>WNFSQZ%/?TNU.N.O,EDYZ^D@GRB M'%X>"J\*Y+)Y"M5Q#34D,KB-#%&"[S.2B(&8V ]^Z\.D'T5E;]35]098E^RJ M*O(O)YXWHXTBJS4S4[U:L%)C>X+?4<&WOPZ\>/1L.OMR[:WGAIV@*P9>B5Z; M(8ZJ6 544Z $6>(?Y1#,DBNLGTEC<."5Y]^X=>Z"ON3*M2[;K:>"-(&@CG+K MJ]3$ A&^H(4D@CCZ?U_'AUKJU/\ E"X7-0]5=B[ARD3K19;,;*Q..E+2.DCX M/:WWE28Y9&Z]:H.L;4Y6^H'CD'^G']"+_GWZO7J==^-OMK7_ .4F M_P!?QX_]Z]^QUJG2A]ZZMU[W[KW7O?NO=>]^Z]U2U_.5Z*W9OKK#:7;.S\+6 M9>+K:EW-3;[CQ<,$E33[9JTQV5Q^X,HK.E1/@]KU&,K/+XUE,!R!E*K$)G5Z M)J5!\^J,//K7 Z/S&;BJ\H@IZK'XV:5J.*>CCGE1X8)7611*%(D M8&YX &S3@>O"O$="IT_TU\>-E[1JW3LZCR.V,CBY?N-M5FY.1@=_9UKI.U#;U[=[!VEU?@8O+ MN+?VY,+M>@B9IVIX*C)URX]ZFK,23.E)1^1I)W ;QPQLYX7WXF@KUM14];R^L<=4)7R[>Q4*9C+)$8?XSGIU$N7R0CT;-J:O3X%!3H9/=>M]=:1_3\W]^Z]UC:($?U_P-C_MOZ>_=>ZP_;C3I MMQKU6X^NFWU^GOW7NI?OW7NO>_=>Z][]U[KWOW7NM=[^>C_-OZQ^(/56X_C1 MM"JI-T]X=LX7^ZVZZ>/P5>$ZWV%NNG:DSB[DD24S#=.ZMO5$M/0442F:FIZK M[Z5HP*5*FZC\1X=:/IU0-U3O2+&4_P!JQC;+;4WK&V0:EE2H@J,;5"HQL]52 MR(1]Q1N]0DBR*;,@!Y!/M2#TR1T9/L?:6U>VLQC&I:%YZ:PFTAD8?7_"WNQ /502.A?VWU5L&/&OBH]C8Z.E?&+3"% M*[)TN.,$JLT0;'1E*&6*.34!#)$T0L0%L??J#KU3TKZ+&[=Z[PKRXO$XZDEH MYJVHEEIJ2*F5CEF,U8R:%"M-4U,2O(S>IV /ZK>]]:Z/I_*=Z!7?&_<_\H=P M0H^'V/)D]F=?T\J'R5&\LK0I-N;/V>-+083;F:6B@9=:235\_*O3_=>Z][]U[KWOW7NO>_=>Z:\UG,)MK%UN)E7FS?UL%4=>SUJ[?*_LG>F_-T9G<&XL]7YFNK0K:N>HJJNLJIB6:5W+EKW)/OS?RZ\.K*?A-\CY] M]=5X3,L#+DMOT%##2[0W)X5>-]53MJEAI9)F;]VMH9G M/+.1=&QU0C/5A_5OR,QU-G,ECJKB?]K_(2OW'D)]J[*I),C'6S""LRR)))1PTS*(O"DL)M6U$E[*J,S$@ M#5>Y&B?(=6 \ST9[XC_\*0>B_B?09'XD_(GX_;GP M?DP6Z\K1R;JW#LK=>5PM7'F,[,KUV1J*3*5"35$TG@I(D58@F<58FO3J\!U> M!UG_ #W?Y4G:46+&)^76SML5^36#5B^Q=N[YZ_DQL\Y4?;9/+;GVQC]LP-$S M6>1*^2G'U$A7GW72>K=6:]<=L]6=Q8%=T]2=E;![1VR[*B[AZ\WAM_>F%+NI M=8SE-N9#)40D*B^DOJX^GNO7NA ]^Z]U[W[KW7O?NO=:_P#\YOY[?4_1U?D> MOOC'0[=[PWS1K)!DNP*K)2R=1;>K0'_R;'5>)G@J^P:R(("YH:JFQRAUT5JEO3K4Q^7O\ ,>[]^2V6J\CW7VSG-S425$M3B=H4M5_!]BX"0ZUC M7![/QII\)2SQP-XONGB>NE11Y9I6NWMP4'#K5">/54N_NV_XN6@7(S"%QKM,*CJ][L#X[9B@H6WCA\763[98C[QX()9H\3,_#&7QHWAIF#<$ MW"GT\@@*\5\^J:O+SZ577/5% B4M1E\6,[0D0S4KO*U;C&AF75&PIY'>&.JB M/$D++<$7"E3?WL#K1/1U.C]CXS/]J8N@-!$N/V[3U.\ZVF2!1$\."EI8:)'& M@(JG*5].@4V+J7L/2]M]:)QUJ.?-K%;FVK\KOD(^:2>&IRG8V MY55=&D\,[8O*#&U4,.7Q$\T"F:BJTGI)@MI(V%P;=:ZV[?Y?'_"JJ>ACP_6_ M\P[9T^50/!1T_P B.K<-2Q5Z0E(HQ5]B=8T2TM+5E)-ZW"^C/D+T=\F=AX[L[H#M39/;>Q
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end GRAPHIC 9 j2280752_ba005.jpg GRAPHIC begin 644 j2280752_ba005.jpg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end GRAPHIC 10 j2280752_ba006.jpg GRAPHIC begin 644 j2280752_ba006.jpg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

D_Z"Z4>V/Y6OS=W34K2P=,Y7 M#,TIB\VYZB';],"(GFUM49 11K$0FG5>VL@?4^V9_>'V[@74-P#XX+%,3_U; M'5TY1Y@+(;N M846%1X:J.IH)HMN8^=XDJ:4QZ7+5#PSJ2'BTG3[B+F/WJYRWU6@M)$L+,^4% M0Y'H922_#CHT U-12@ MV[DW9[$B253/,/-Z%:_)1C]M:>O5I>,Q>,PM!38K M#8Z@Q.,HH_%1X[&4E/04%)$69S'34=+'%3P1EW)LJ@7)/N)9999Y&FF9GE8U M+,222>)).23ZGH5*JHH1 @& , ?8.I_MOJW7O?NO=>]^Z]TF=ZTE?7[-W;0 MXJ&HJ,I6[9SU)C:>DEIH*N>OJ<55PT<-+-6U=!1PU$M0ZJC2SPQ*Q!:1%NP5 M6,R6][#/)7PTE1C3C0,":?D.J2J7C9!Q*D?M'5>G^BCOC_GD>PO_ $)NMO\ M[;'N1?ZV[1ZR_P"\_P#0W1/^[[CU7]O^QT)_??2G:>_^UNF>P>NTH]KYSJK! MUFWIMXS92DBJ<_L;N.5-F]T[(K*6!WK_ +W:6'QV&WG@26>@K-Q8"FIYVC0F M3W&S>NMC['HL4VTUZYZ?ZLP>WZ3:F\]H0XRJQ MNV^L-H[0[&ZAJ,G4>7)X[=VXMS8O,Y3$;GBII:*BJZC%2RL1!61M3K?7>R^G MODUMC?E;D\?UU583K3<^[LQF]X[)C[8VK+F:G [FS^4KIL/BLU24J5%/7T== MDZ*IR$CUA2LP^+EI8V-7)%(_NO=*?:76_P FZOO_ &-N3>>QZR3K;9796,SN M*K=Q=I[7W=EJ.'&[+^:G6&0WYX(:&DJ4W%NC:/:6QUJ(*=(O%1P-3#4]--)/ M[KW2D['Z+[,W?DOD!BL#LC!X#)=C?(#J'L+8'<_]X,5'E]EXC:.R?CYA3=HH:N]%4U*>_=>Z3^R>E/E%F:[K3*EV9D]M9G;./RNY.U]@0[7JC7TN\JO>^RZ6@PHJ3#+CL; MN*ODDBU* ONO=8=L[!^8&,V)FJ;(8JO.]<+5;?K-D5--V1M62AK]CI7TR[^Z M]SE$E'C\5-OG==)1Y&IILLT<=#'55^),DB"BK5;W7NA>Z%V+\A-M]GY7+[_R MU;5=:5^SLC3XS";ER.WJW<6U\Y/5;&R>$P&,JMJU-1193;6&AGSE!>K_ ,HI MVHXIHYJA:^40>Z]T67*]9_.C=.V.Q*"2GWGL7)9F/L[.;,CV]WKM67^#Y[(_ M'#KK [!H:G+G#R5=2U'WYM?*98RZ(J>&;*R3-&\!$2^Z]T8CK'8'<[?(O']D M=B;.^RH\1MKY.[6.[/[[X;,Q9'!=E]O=2[QZEQ=%MZF45N-7:^PMA?PRL-HU M-9 7_>619![KW1X/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=$T[\P[9'N79%1D-I=OYW:M-E\CUG'N0Q46[)]W=(U&Q8HI,/D*:BC MWDM!1Y^3&-+$Y4"74=)TGW7NBO;([/\ E]UQAML8GMK:6_*W>F.W+T+6=J[V MPNP5R?6E7B<=UK\0MK?(;-U^YXF/W!A_CINWLM=M/T6E7EJGM6GV_P!4YGKFBAKY M=PO3?W,[3WG3;YI,1CN:O^&T)@EEC>&*63W7NAR[ [ ^9L%-'4[&VKE:W(3T MO;DNYL#DMEY&DH:?+87>=,_5&+V/N''O62)2YW8%!D$-550R4]1E?L&K#10U M<_A]U[IEV1N[Y,XC?&Z,7N':W<[;>RV\9-O5>[:O9<>?SFW]KP]R?-JHQ=;@ MJ^GJHL5GL12[G<#;VVJM=-C MZZFK.JZK(TT^S:3<5#5U^Y:6/$9?%Y".:KP.9P=#C: 5[TYJ\74BHCJ*6=Y) M:B*'W7NE'V\V\I:3HJNIL-N>7,1=L;"J-W8_97WN2QV)Q\])6KN2IS$U.:9I M]MXZ20Q-+,#&4DU&,MI*^Z]T6KN'KO=F\^YZ;L#:>;S.3%3B(Z#=.SJS ;VP M^Y=@;&V7'!O63'XNHPFYJ7'9B'M?<^T8<(^/EQO\3EH=RU-52U8%(L+>Z]T, M7QS;NO#;AW#M+M/"9[*2TF+H7R?8^:J[Q9*MQ.!V/C]LT>-6%CA,E)F:*KR< MF2?&CQT^4QL\T^ELA%##[KW1O??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW2"[5W'7[/ZO[(W;BRHR>UMA;PW'CBZQN@K\)M[(Y.D+I+'+$R_<4JW M#*RD?4$<>S#:;6.^W6VLIB1#-<1HU,&CN%-"016AQ4'/ETS<2-% \JTU*A(^ MT GJE/\ X<6[T_XZXS_SWX/_ .L/NVW,GLN&F>FM49S-8]EF012(\!3((Y61>"L1^P]"Q350?4=!'C?G958 M+XOT_RK??;#@GWC28 M:LK9)7%&TTM5.!28_(RP-];Z$/ _)[$X3=F>ZAVKTY0X+?N!WK4[;FVOM^MV MX<168.#"=/9K%9R"MVZ!2QRT^WNZ\=45%,R%X8<57*FK52>;W7NE3MGY";M[ M4^.O9O:6 Q^+ZPS^W.OJ]J9-QH=QS;%[=PNSILCOK8^\,/Y<12U]7UCO0C"5 MZ05:I/74E3$KH8_?NO= -M;YY[AR5&NZ=R87;.VZ;$=+N=S[!R>07$Y>+Y&; M3W3DMI=K[,PF:RD\,F( M@R61KT,*R5#2.T4$8DD]U[H:66IW!_&>EXGIH*@0QRXW,Q,S+412Q+[KW1U/?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%K:*DR5%5X[( M4T-905]+445;1U,:S4]72543P5--41."DL,\,C*ZD$,I(/N\M$!@5854]!Y_H7ZD_Y]OLS_ -![&_\ U/[,_P!_;W_RF7/_ M #E?_/TS]+;?[[3_ 'D?YN@=[B[-P_7G;O6.U9=C[,R]7V#M3)S19BNI*FIW M6^-V-VETY@3MC"4=!@20Q"TH*B234Y)Z?Z#W M+]__ !(QNT,'EX^KZ_/X"MVAA:/;6(VS\?,ON&JJ]G[NZ1W5VYCL#AZ66ZFV3TK\9.P:[&X>'MW;/7FS-^[OW+C,M5;9R-3OS)4YR^]]^93=,ZT5' MMRKSVY,U55N3R9%+$LU7/*R0AG5/?NO=2>W*;KC"[DZJQ^=Z5VION3L3=6Y= MFQY"IVSM7(UF&;#===G=S1Q14^3HY*RO?-9/9=4D<4/I%;6-,Y#$EO=>Z!CJ MO?'Q^[6GP^Q,CTIU5MQ\YA]T8W+[:S6VMG/1SS9+#P[4@VKB<9-ATCW NY>N M=M3P9*(1+'#B\?!2S*\4D">_=>Z-W1=8=:8W(3Y;'=>;&H,K59Z+=53DZ+:6 M ISL#[KW2Y]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4/(U]-BL?7Y2L<14>-H MZJOJI&:-%CIJ.!ZB=R\KQQ($BC)NS*H_) Y]WBC>:188Q61V ]230#]O6F8 M*I9N %>@G_T\= _P#KS[./ZN;S_OAOVK_GZ3?66W\7\C_FZ8M] M[QZRVAVILG<&YIMSG>+]>;OI-LC&87+97#4VR.+< M+;8%7--+_D\?A8!4>0N2D%25/$=*ND?BOC9\<\?C\:=MNN-QU!2T5!CI MHKJ2&DI>M-V=4;6I:9LE7Y.GABV]UENW)XS'K%IU4\IDF\\L:RKKKW7ND^M/ MCABEP?;G6RSTC4F'W/BL76Y;<>X*&'$T^Z,M1-ON:7:V2R%+BL37;RW#L>&M MR)>CC^XKJ-JE561YG?W7NA3R^Q.HLQL;>O5%)3;5V[M3=V/S^.WC@=H'!;=^ MYH]Q228/@J9)\W#LJHZWJL@:_-U[9S.[,QFJ& MDQ-3!]ED[*WCV#N;-TU/MC8>!W M!N/_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF'=6(DW!M MC<>!BD2&7-X',8B.:0D1Q29+'U%$DCE4D8(C37-E8V'T/T]J+2?Z:ZBN2*B. M16IZZ2#3\Z=4D77&R>H(_;T2W_91LY_ST6)_ZGUG_P!:/8W_ *ZI_P HY_WK M_8Z+/W8?X_Y?[/3_ -[;/Q.7[9Z>KZG=_6N,W'MK8^Z-M;3VSOG+YZ&3+YK> M'8O266Q^Y8<#AJS'+N*';>X^L<;!3T=0Y@J*S)IY#'XD2H 3MJS^>F-)% CI)7QU M%/[KW4?M_P"*F9V=AZ7>F-'7U+E?[[=AU>]=\XW:]+%E*G#=H_+C8/RHILIG ML4:&>NW)3;8W#LR3"18T/DVE_CDE5XI LT$ONO="%\<_C]'TGE<%O[L&KV12 MY#,N4HTANFOQD>&6"BSV5K M1 &CB@G7W7NA&WWTSMSNBLWG%4Y?K?=VU.U-^=";XH]Y;9 MW!NNAEQ=315N.R:9:MQ$6-D(UQ00US&3U!8I/=>Z ^J_E];NR.VNRL)E^XMG MYF;M6CWYC=PP5_2^-.W*$]D=,=0],9S<^/V^FZ13U&\,%CNG*.KQ%9,WFA@R M>0H9Y)A4&K]^Z]T)$?PUS4.?R.[7WGM3,[KC[1W'V/09G/[0S>2@W5C-VY3? MF6J^ONQ\#5[SJL)F]M;/GWU;;4D4*38F3%4$J@^&2.;W7NC5]+==OU#U!U?U M0V7I\^O6>P-I; I\S2X6+;L&2HMH8*AV_054>"@KZ]T)OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+ MEV3U%D^Q.ZNLMSU-=G,7LS9O7G8^%S;8/,4.+GSF7W3V%T3O#"X>J'V\^7;" MB/J.H6O-.]*[I51QK(P>7Q^Z]T4.;XL?('+[4V]MG>VX\SF8J' ;8Q&I\I%')659@KP1+[KW M0O\ 2G2G>6 [@VIV1VC78+.S8787=6VZ 7(?&SL6;:O66TH,Y3PU77O1L?2.#WACMQY>BJ-OY9-N]9@]G_P % MIZ?&P9JEJLGM?(4M;AZAY5K8H*!+PQ5-:]/[KW3IUO\ '7L'JSL3!9;:VY*. M/9)JJBGK\9D/L:^NQ>U8JO>$]7A))/X53FLJ]V25^#JRV,.)CI*Z@E-8^4BA MH47W7NCN>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7N@S[JR&?Q/3G;.5VK)50[HQG6>_,AMN:BA6HK8L_1;6RM3AY*2G>.9) MZI,C'&8T*.&< $&]O9KL4=M+O=G%>:39M=1"34:+H,BAM1Q0::U/ITGNVD6T ME:*OBB-B*<:T-*?.O6O5_LP/SU_YZ/L[_P! _'?_ &.^\D?W#[;_ .^[#_G( M/^@^@-];OGK/_O)_S=6L]_[][NV5O/:V?V568;=>%H.N-GY'.;!JQ,M?BYVKZF&/WB].%$[A M*: YI]E<=#]*E!7C0=)#"?*#ON>GVQCFK.I M^6P.U*_'_'J:CH:[>V5DWID*C/O+29J&>2FK%CEHH*.3(TM13*UU;I\SWRAW MIC:_K[E.UMY]C]7=V;XW349? [KKN@>J=UY[;I&:P MC;"W_END*JLWMA\=A*^NJZ[:-=A]UTDT,]*LOFIZJF.MFF#.WNO=)K%]F?(3 MI_:>WZW-Y#"[JQ?9&SGWSLBB%+NC?5;A,CCX?C%AH]BPYN6#;V:SN4WT-Q[Y MW!'2RQ5-31%6,$LU'1_;1>Z]U%I_DE\B*C<];0TV?ZJR,IR_:&8V?L.BZ\W, M=P=B8'8W?N1Z?VYL;#;@;?K4>+RN\\'AX\L-QS44F.H4RJ2STJT-'+5R>Z]T M[O\ *#Y#PML2:/KO&9FGSNT.MMS;\QN,V]F,=N+8>ZLS59F@[!Z;Q\.YLWA= MM[O['VK4SXV;^%IDZ7<+X^GK98,353M24T_NO=&0^,O:N^>W]JY#=>\H=G8X MSC!.NUL"NYJ;=76^XJK$I5;NZL[,Q^X,;1I1[TV/7R115 1HYBTQ$M+3JL+U M'NO=&6]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=$D^7G?E;U)6=98AL#3Y[K#-;LQ&-^3-=)C]QU)V=TOV16GI_&9I\U@TC MH-EBFW]O:CSM9DLE40P+M?:V=\0\RK+![KW7.A^2D>%QN'QFT]G;<;:8Q_:= M!L:7(;\KZ2JEQ7QWR.Y=J[YPN:CKMN5E1CMY02X&B-!B6GJ\C/"Z:=K_-3?F]NVNKMB8GK:AVY+NS MFW-ZY+,XC*;3GQW5_878]4U-E$VU+C-P5DRX#$K15F.>MVWE*&O^YHLG41O& M_OW7NO8#YSYZIZ8ZR[/_ -&T.<&^&H-LR8N3=%/@]WXC=$.R*;=M9G]Y;8;% M5M+M?9.:I87GQ]3%6UL\]/F,)*(/#D?)![KW1J^F,I#V51-VYN':6.VSV-19 M3M+IO,18?<^5W'B8L?UAW'O+9LPQ]554&WZ>LH\QDMJ?Q&*67&4]9''4B)C9 M2#[KW0[^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_ M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[HJ^^,U%N_M7L_I[:W776F:W/M[I7K?L;>&5[.QNO;V\\ M;OS=W:V"Z\V%53T6#R]7)C*?+=/9B?)5\Z5?\#6>BDI\?7M42K3^Z]T&>\>V M^B]QXK!;/?IC.9.D^26%EK=A5V'VKUM >P=ONM#M6+>M)69W,0T>(GQ%%OK% M24:YZ.DKOM\NAAII%AKDI_=>Z9-J=\=0U6TNOH-L_'3?6]\UO6#K7;VVL768 M+I<[NW7CJKHV?NW8VX-P9S+[UP^UX[[0Z_G"BLK:>I@R>-55IXT--(_NO=.E M#\A_C9NUXJ7:?3#[WDEP?3L^V:*CV+L&@J\SAN[\KV9DMAP4^-W5E,'6[9HJ MG-]:9"K=)VEA.CZ_&/G-H];Y>/!; MGV[U?2R1=/[MZVPG:&R][5. IMSY"ODZVHNLJ=G5&+K,9C>P.Q>RMH;"RM5N%-OL M5DS&#K]YPU^2@D:.JE1")'C+B1?=>Z8<[W9N1.HINP-O8+!2;GH,]O79:;-R MN3K8)-X=D;'WGG>OH=B[2K5H4(I]];OVW404&6J(U6CHI8ZV:DDC$LZ.1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[IDW+N#&;2VYN#=6;F>GPVV<)E=P9:>.&6HD@QF&H)\E7S M)! DDT[QTM,[!$5F8BP!)]OVMM+>74=G 9Y9%116E68A1D\,GCU21UC0R/\ M*@D_8,]%$_X<#^,W_/6Y?_T$MS?_ %J]C/\ UN.:O]\Q_P#.1/\ /T7?OFP_ MB/\ O)Z%'LZJZ-S66QN.WQBZW<>YJW8V6RZ83:^ WON'=.1ZWFJ:*#+X_<&% MZ_HJW,Y;8V:R$\4,F+R,4N.R50AC\$SQL% [J48HWQ T/Y=&8-14<.@II]Y_ M"O<>:VK4X/<6PFL[MW/;LPLV]L MW3%<91=-]A],;$P.5R51O>AFVCA*;9N_J\1(4TY!8(U<.B-?W7NG,=;_ !8V MAO?>\=!LF?!;NZVV]MON?=";$'7N=W7ELW6Y6&2)MZUM?#3U,D214S0Q+$JPK))[KW0A[M[CZ?J M,KFM@[SJ:VDI<90QYS,93+8C.8G 8=<+G'\69EW(8*3^!K@,GBHZZ+,"2"EI M"L-1%5*WC8>Z]TAL]US\4NZMO;;IAV]48S/X"CWC35^S]YI$/ U93S-5U,$FJ?[E![KW0I9'#]-92+ ;ZEHL/ MN*'&;QCAPV;PYKMQQC=>[=\;E?%3[YQN*J)#5++28FIQ=-5M]N, M?%+![KW0@[=WCM+=XRC;4W/M__=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z2F_-K1[YV-O/9,M8^.BWAM3<6UI,A' *EZ"/<&'K,2]8E,TL*U#TJU9 M<(70.5MJ%[^UFWW9L+^"^5=303)(!PKH8-2OE6E.FYH_%B:(F@92/VBG59__ M UM@O\ G\>5_P#0+I/_ +)?M)U[UOVA2[Q7NOK[JWLG=_5.W>NLCC-_UF&GI]Y[2V%NW(OLC,46W:[=FU MHCEE-$8HFD?Q)&DX:B3^T]'X% !Z= I2_R_ M\9M_9F;ZXV=V:^/V3D=H[RVM0+N+9J[CW52S;R^->R?CK6YW([@H]U;=QF2R M3P;)3-SB+&4<<]563P((8BC)3K?2[I?B%,^X4PN-Q-5N+.^PQE)!#6192H4UC M>Z]TI>Z_CCNOMBN[>_A79>W=JX'N7J#:W3^X<=DNLI-WY&@Q.UV[BJX."Q.LLHG@]U[H*NM?COD:/LO>>Z1NS_@3MB3$[1KMB=P;;RO6"Q8_.;'GQ^QJ7/5%;M+(TS38W*8W>]#OP8G M*Y/,[>R+%LU3T(BK6J7J/"4E,9]U[I50_"+*T%;496M[@VY*F:K#3[@Q-1UG MD(MHUD-7LOHS9F,K\;M>7M23$'?-/N#I'&Y.*KRZYO%U576/'48N=HZ>2/W7 MNAAI_B_%C^GZ/J;&;S>6EQG:_7/:&'JMUT&Y>P,?@4ZT[%V3V'A=HXF/>>_L MQO-\$*O8\,$/W^X*]\=%420T7V]##14-)[KW4?IKJ3;/QC7$4N7W]MD8V@Z' MZ*Z8I(8-JQ[*H(,=T3#O+%T>[\K4?WBS&/H1N$[[AH[2BGA@D@I::.65Y(T] M^Z]T)>^_DM\<^KM/DJNGQ^/GVG M0Y[-T%5N*&OKZN*"%J19EEEE1%)9@#[KW2UA[+Z]JL5C\Y0;TVUE<1EJ7(Y# M&9'#9BAS-)7XO"92BPV?S%)-BYJM9\+MK(Y"%,I6+>EQH?74R1(&8>Z]TMM: M?ZI?^2A_Q7W[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$"^45350? M(7H<)A(1F?&;)K^CI=\=LG$8W:JH*/(9K;.4FE=<7G,7'#F/=>Z1-7+W%)@=@ MT^8H>U:/L.# 9"DW[EL/E<#DL3D\EC]H[QMO8'#8F;!=X;O84\8P^P MLID>VMN9QH9),GG,(N1B;W7NCP[,;E*?(=+T-#B:JHQL6/-8ZOW-3]QMM+ M[D;>IMSM+7#*?:G,3F;[P>_=>Z*?UT_8+=)]5P[#I=_Q]&BM^4DGQTR&$KMI M3Y9_B[3;SWS6;2*KS6RA3X[I^IZBKGS>+VD<5DTV^-W83NO<\6ZG[.!P M%-M9OCQ/V[38=,#UW%.L=;V,E/L^M2IGCK*ACONGI]_08N84^<$NX(9JF?W7 MNEOV]]DO<]6\?\:%/=>ZR[*../QZZBBW:E.O3\&9VL,W79.4.^3P:BE_NP] M=BFB2'!;/F[:GIC0K25F12/;U+0"9GIZJM-'[KW0!])>./N"D/3G]Y*O:4TC MR5J9O^+X[ 8[:%+'V+-5T GRAPHIC 11 j2280752_ba007.jpg GRAPHIC begin 644 j2280752_ba007.jpg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

-@H:]ZN;!T4='+6 MYJOB^V'\%Q=+_$((VFK33H:B:.G4M421Q-[KW2L]^Z]T3_X(?]DS;7_\2!W_ M /\ P0O:?OW7NC@>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7N@1^1/>FWOCAU-N;M[=.(S.=PNUXHI:O&8 4)RE0)F***<9& MKHJ2X(YU2+[/N6=@N>:-[@V.T=([BO5/U+_.R^(]"[R47QU[&HY),AD\M(]+M_K.G>3*YNG%)F.TZ+*RU6V:BHJ:''UN-R>X<9645)6O(0[E2Q5?3_ %]Q ME;;#OE["+FSLKN6W:M'2&1E-#0T95(-#@T.#T(Y+ZRA>%(*#,8'-TNX<;4QTZ+&!%EZ.KK8JQT4#4QE=B>6 M))O[*;FUNK*9K:\CDBN%XHZE6%1455@"*C.1PZ51RQS()(65HSP(((/YC'2A M]L=7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)SL? MXOY;8\71IH=S[97='3NWI-M5_9>,VQDL-G=][5DRE34OU[F]NKN.NA;9Q@K9 M*M!/E:QZ;,".IIXX5^XBJO=>Z'7I[KW(=8[+3:N3W!1[FJDSNYSM=EZ>C_ (;49W<O\ ;JZV_O1M2?;K]@;:Q4^'S,NX]J9BL;*T=7!/6IF]M;MZ\QM1"C. ML25%&8YXIHGEB<46?)/-VX6J7MEMMY+:2KJ1UB8JP]00,CHMEWC:H)&AFN(E ME4T(+ $'Y])+ ]U_R]-OUN!KZ;Y.=75ROHWBNXS1D8493Z$'(/1E#-%/&)H6#1,*@C((^72A]ING.O> M_=>Z+SVWWK4]75>^:=-HP9Z+9O0^]NZHY6W')BI,I+LO[QY]KO"-OY-:".NA MI@4K@\Y1F*FF(74WNO=.>5[TVSB^T>K^K:FIHX,]V1@JIGJX9:7&C M*T5%!%)5TLTYFHJ.MDD:.&5HU@0E%64,/=>Z&^8S+#*U.DP9A&Y4I>[L&] M?N&NRF.CSG:\_8M!!MG*I3X+'U*XG UVQHR];"6FJHJEK00M& _NO="OT]N; M>&\=@XKZ![O'=&Z<9V7M7;N"WACMN8S.]+]O/5IN/<$VU]H1[V M_OOT=@NLY,_N+&0_Q_"2YFIW%E:"F^RGIZZL$DL=&\=2B3P^Z]TR=7=@;ES> M\/C/CY\QO<8_,_'#>^2WQB-[4M%39N7?$<'QWS&V:K=DE!04N.GW:V&W)F"W MVCFE:1:U8E#03A/=>Z,#V?VYUAT]@Z;.=I]A;9ZWPV4K?X-CLUNC+X_#4LV5 MEI:BICI:2?)$TTM:*>FDE5"K@K&25(!]F>U[+NV]SM;;1;S7-PJZBL:EB%J! M4@>52!7Y])KF\M;)!)=R)&A- 6-!7TSU7)@-R_RX-O8&FVS!\L=D9#")LJCV M-7T.7[)Z\KHR.F>YMB]E M[FDDS^_-Q18+[V5S;6S.$#2(RJ6(+!02.)"L:>@/2BVW/;[R0Q6DTGOLGJK/[Y[,VAN6GR%+C=LX;JOM;8^7>FR:TVXJG(;ZWATIN;' MT]-0Y#:FX\!5;>JJ3JRIH6YZ@[AAZCVEV'!EJJ7;XVMM_;&Y8-\[E[,DI[9&G2;$4> M"IZZ"22NK3'CO=>Z/7[]U[HG_P $/^R9MK_^) [_ /\ X(7M/W[KW1P/?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= GNZOWS1]N]<4^'WGCZ39E70[D MR6^-H5FWL6TIV[@\+DHGW)3[KJLG35="\.[\U@:=H(X)[P22$J%+2P^Z]U-Z M,WON#L+8,VX]T#%#+P]A]R[5/\%H:K'4!QNP>XM^;$P+_:UF1RLZUKX+;=,U M4_F*2U1D=$B1EB3W7NEMOC=E!L/9NZ=ZY5#)C=IX#*[AKT%124A:DQ-%-75 M^[R$]+0TH\4)O)-)'$@Y9@ 3[]U[H#)_D]MBA/4$5;B?O9.W,=B,SCZ[:6X\ M!O#;=)B-P[_V#UG@\CCMS8JJ&-W+2U^Y^S\/():4B'^'/43J[O#'!/[KW1G/ M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5X?S4 M/^R).WO^H.A_ZW-[DGVB_P"GA;=_II/^K,G0=YK_ .2#/]B_\?7K2C]YU]0I MT=W^7)_V6G\?_P#P_L+_ .YD/N//=?\ Z=YN?_-*/_J]%T?JWOZNPJCJOK#=6^J+&C+U^&@QT&.QS++(E3 MD\WF<=@,:)(H7ADGBBKLI&[QB6#RJI4RP@^5/=>Z"["=\"NW9TY@*/)TV5VI MV+MK+50["RVRM^X3'[@W9BJZHQTNU<5D8L =D;4ST]115$M-C,MDTR%;3PL* M1*KQ23>_=>Z-'[]U[HNF+[XH\QO3LG!TCXF+';'@W'CL%1UD.8I,GOKZ%KKW=J[]V1M;>:T#8 MM=RX6AR_\.:I%8:(UD0D--]V(*45'B)MK\<>HLQ-+@:[*8F"7#9_OVMD\G@,TFZLYBH-D[>W!5 M[IES29,;>HH,-G\E-CJ^@EHHJH.\$L1,3 M[KW1)OYX7_9'^V?\ Q.6U/_>% M[+]S#[&?\K_%_P \L_\ QSH)\Z?\D)O^:B?X>M2'WFGU#W5L/\F'_LM?%?\ MB.=Z?];,+[B'WP_Y4*7_ )Z8?^/="SDO_DN+_P TW_P=%!^;7_97WR;_ /$\ M]M_^]_N'V*/;;_E0MJ_YY%_X\W19S#_R7+K_ )JG_ .BN>QMT3=;S?\ +P_[ M(J^.?_B-,#_[C^\!OIRY<_P"2';?\T_\ *>CH>P)T M=]>]^Z]T1KLWNKX7YC=&\\9V+NRJFW"=K;QZ0W?1)1=PTU,=N563J\=N[;C1 M;?H(,0TTF0IIHOXA3#[H("(:@1L+BFTY+YFOK9+RUMM5O(H93XD0J#P-"X(_ M, ](GW&SCEK*9\=3*D<-0DL,#%I(E21W=E']0>;?^43_ *JP_P#6SJO[ MTL?X_P#C+?YNC2S]G[(J]GX#=U/DJRMVQO18X,)D:"ER=%4545=B,AEHID25 M,?E<<7Q]!*RN5BEC?3;2UK!]MJO4OGVZ10MY&2&4D&A''()!X^1/2GQXS$)@ M:QG@>@9V]!\>]J"B_NWALYACC=H;7V%0M097=T+TNT=E2YB?:N&AD&>+K%@Y M\_6O!)?S!ZAR7)L0H_<.X>B_[UU3ZJ'Y_LZ&79.[]E5-/C=K[3@FHJ+&4E-C M,;0+1O3TM'1TE',::FBUNQ$<-+0L!]?H/Z^TUUMEU9QB6<*$+4P:Y()_R=7C MGCD.E:UIUKU]Y_SG^[MC]J=I=81].]+Y[ ;,W]NC:M(^=H]VU4V0I-M;AJJ* M@JLA"NY4HI*LFA24E8U42BZ@6%LDMC]BN7MUV6TW.:\O5EN+:.1@/"H"Z!B! M6,F@)Q4D]1W>\ZW]M>2VR10E8Y&4$ZJD*2,]W0?#^?'\B1P.GNE0!P (]\\? M^O9[-?\ @>^6O^4V^_ZI?]:^DO\ 7SJJEHX)ZIEC$DDCA +L3S M[#7L_MT6S^Y6];1 S-!:I<0J6IJ*Q7*H"U !4A:F@ KP'1CS7<-=\NV=VX > M4HY X M&2:?+/6M;[RBZC7JZ/^19_P!E<;[_ /%?]V?^]_UC[@W[P/\ RI=M M_P!+2+_JQ<]#3D3_ )+$G_/,W_'X^B6?(WY"=^8OY!]Z8S&=X=OX[&X_N#LJ MAH,?0]E[SI**AHJ3>69@I:.CI*?-1P4U+301JD<:*J(B@ #V.N6.6^79>6M MOEEL+)I6L8"28(B23$I))*U))R2 MV_S]; /^DGL7_GOMZ_\ -X']FG]C_OGA_9?\+^#Y=2!]3<_P"_'_Y5_7\1^/\ MCX_%_2X_/JT#X(?]DS;7_P#$@=__ /P0O:?O'/J0.C@>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7N@P[H[3Q'2756_.V<_CLEEL-L#;64W-D<;A_M3DZVDQ=, M]3-3T7WL]+2_<2(EE\DB+?ZD>S;8MHFW[>+?9K=E2>YE"*S5T@GS- 33[!TE MO;I+&TDNY 2D:EB!Q-/2O5-]=_/(^+>4=IVJ2=,9L/&X:'<6_M MRTF,ESF5AQ.X6EE:?)Y3[BKF6*2>4ZF.MSR5[W[(;_L>T7.\7%W9O!;0M(RK MXFHA14@50"OVD=*;/G.QO;J.TCBF#R.%!.F@KZT;JPGMOY<_'#IS.U6Q>R>[ M-H==[T?$0Y*"@S9J9*REI,C]S#09(4RTLE//&9J9RJLUB4]0L>8\VGDOFG?+ M07^T6,]Q9EBNM0"*CB.(X5Z/KK>-LLI? NID26@-#QH>'10X_D;_ "\$&QL? M+\GMBUVW=C[H3?U/BLBT4];D>P8]T9C?+;J?-0X&FJL-)D][YV;+9"FQJ4<% M34P4U.@AQJ3T%29_ZV?/O_1KNOV#_/TG_K'L?_*3'^T_YNK".J.YNKN\MN56 M[^I-ZX;?FVJ+,5.WZO,8*2:6C@S-)1X_(5..=IX8'%1#196GD(M;3,O/L,;M MLVZ;#=_0[Q ]O=Z0VA^.EJT."<&AZ,;6\MKZ+Q[1Q)%4BHX5'$=";[+.E/7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7A_-0_[(D[>_Z@Z' M_K:_^2#/]B_\ 'UZTH_>=?4*='=_ER?\ 9:?Q M_P#_ _L+_[F0^X\]U_^G>;G_P TH_\ J]%T?/5% M4TM"ZK4T.2H!+3SPN)(9HDEC9756 KV_DOF#=+-+^SB5K:0$J2Z"M"5.":C( M/2&7<;6&0Q2,0XXX/05XSY-?"W$3;>:@S.W\-)A-]56#QN5F$H; M.)B:J">CGSB+/+XZN59)H6FE>-EDEE=UG^MYS5_OA/\ G(G_ $%U3]ZV7\1_ M8?\ -T<;;?;6P]U;5Q>],3F6.WLS.]-CJRJH*^E>>>/&3YEX_MI:85$97&TT MDGJ4"R$?JL"&KO:+^RW!MLG3_'4I500>(#<0:<#Z]*TGBDB$RG],^?\ +H,: MS;WQVK=R9'=DLDL6;RKY":LEH=P[^QE!]QF,6^&SE9283&Y.DP>.K]P8]E3( MSTU-%-D'AADJ6ED@A>/W[HW'_?1_:/\ /U[ZB'^+_#T(NP,CUKMS X+8FR,B MZX?;N.HL3AZ&JKMQ9FK@H8YJ>@HXJC,;BEK\MD)3/4QH9:FHFF8M=F/)]LS; M?>6\?BS(52O&H_R'K:S1N=*FIZKC^0?\V+XF]9;YW[T5VCU=V[O&?;.6JMN[ MEHX-D]:[AVAEIL=5V;QT^XNQJ!Z^C%33AT^XHXS=0=((XD_E_P!F>:.9-F@W MRQGL$M+A2RB1Y0X 9E[@L# 94\&.*=!J_P";]MV^[>RF2M42F7(U J\I)047^F'[#'568 MJ462MFIXHYJUHT,[2%$L<_\ _]H_WW<_[RG_6 MSIE_FC=W[4^17\NSK/MS9./W#B]M[I[LVQ48^BW328VBS<*1[([*1A64V)RV M;H(V)^FBID'^/M1[7;#>#"M5&>J>V__>_W#[%' MMM_RH6U?\\B_\>;HLYA_Y+EU_P U3_@'17/8VZ)NMYO^7A_V15\<_P#Q&F!_ M]Q_> WN;_P K[NG_ #TG_CJ]3ERY_P D.V_YI_Y3T=#V!.COKWOW7NM9'O/_ M )G9W)_XEWM/_P!^#N3WE'RK_P JU8_\\R= N^_W,D_TYZ"SV(.DO5YN"_[) M@^/'_!=O_P#ON-V>\>K[_E=+W_3O_A7H4Q_\DZ/[!TF_9GTQT,'3/_'S1?\ M+8?^ZG.>R'F+_<%?^:H_XZW2JS_M3_I?\HZTR_E;_P!E.?(3_P 3/V5_[U^6 M]YOH4W;_DJ7/_ #7D_P"/'H /8CZ+^MA7^8;_ -NK M_@I_U!]0?^^9RWO&WVV_Z>_S'_S6O/\ M,'4A\D MNH]ZNC_D6?\ 97&^_P#Q7_=G_O?]8^X-^\#_ ,J7;?\ 2TB_ZL7/0TY$_P"2 MQ)_SS-_Q^/JLWY-_]E(=_P#_ (FKM'_WM\Y[E/E3_E5]M_YX+?\ ZM)T&=S_ M .2E_TL]5_P#/R^O_ /T,MN?_ %R]^Z]U[_2S MU7_S\OK_ /\ 0RVY_P#7+W[KW7O]+/5?_/R^O_\ T,MN?_7+W[KW11/GOVAU MI5_#;Y&TU)V)L6JJ9^J=VQ0T]/NW 33S2R8N=4CBBCR#222.QL 23[&GMVR MISSM;.0%%XE2<#CT3[^"=EN0,GPFZT<_[S[:_P">AP?_ )]J#_ZH]Y[_ %MG M_OZ+_>E_S]0=X,W\#?L/1E/AINK:\7RX^,$DFY,!'''\@NFWDD?,8Y$1$[%V MXS.[-4!555%R3P!["'/]W:OR1NJI+&6-C+0!@3\)^?1ML44HWFV)5@/&7R/K MT<_^3^9X! M']?8.]C[FVBY&5)9$5OJY<%@#^'U/1MSG'(V]$JI(\)> /SZJ<_O/MK_ )Z' M!_\ GVH/_JCW,'UMG_OZ+_>E_P _03\&;^!OV'K:\_D@]A[ Q/Q%WE'E-\[/ MQLDW?V[GB3(;FPM&\J+U[U4K-&M16QEU5N"1< ^\./?22.7GC7$RLOT4.001 MQ?TZEODI679:,"#XS\?RZN+_ -+/5?\ S\OK_P#]#+;G_P!_=>Z]_I9ZK_Y^7U__ .AEMS_ZY>_=>Z]_I9ZK_P"? ME]?_ /H9;<_^N7OW7NO?Z6>J_P#GY?7_ /Z&6W/_ *Y>_=>Z]_I9ZK_Y^7U_ M_P"AEMS_ .N7OW7NO?Z6>J_^?E]?_P#H9;<_^N7OW7NO?Z6>J_\ GY?7_P#Z M&6W/_KE[]U[KW^EGJO\ Y^7U_P#^AEMS_P"N7OW7NJ^OYHG9?7%?\*NW*>@[ M V36SO2T"I!2;KP53,S-.P55CAKW=BQ^@ Y]R/[2ND?N!M[R$*@:2I)H/[&3 MS/0>YI!;8IPH)-%_X\O6E[_>?;7_ #T.#_\ /M0?_5'O.3ZVS_W]%_O2_P"? MJ%_!F_@;]AZ.Q_+IW=M2G^9_0,M1N?;T$2[^PNJ6;-8V*-?\LB/J=ZE5' _K M[C[W4NK63V^W-(Y(VNK:/V_LDDD1 M7#38+ '^V<\">GN;(Y&WV8JK$43R/\"]5S?WGVU_ST.#_P#/M0?_ %1[D[ZV MS_W]%_O2_P"?H-^#-_ W[#UN8?RJ>RNN=)/<"^>,AD/A9!J/[%!Q'4S\J KL4 8$'N_X M\>K%_P#2SU7_ ,_+Z_\ _0RVY_\ 7+W&G0BZ]_I9ZK_Y^7U__P"AEMS_ .N7 MOW7NM=?Y3;\V,_>_8Y3>>TW']Z]R2?)$T*(_P#HOG]^MD_\]CM7_T(<1_]5^Q5]1;_ ,:? M[T/\_2+0WH>KH>F^Q^O(_C+UIY-^;,3Q;BKEEU[HP:^)FZQW- JR:JX:"9_0 M ;>OCZ^X%W]T;GF=P05QFN/[)>A-; _NQ1Y_]#'K%_I-ZW_Y^#LC_P!"O __ M %?[6:T]1^WIFAZ$7K#L[K8;EC!["V.-38I5ONS C4PW-@92!_E_)$4;,?\ M:5)^@/LHWQE-@:$'N'2BV!\8=:JG\P_=NU*CYG?(&6#1/43\S12MOMR55B-8\ MC_"O1+?[S[:_YZ'!_P#GVH/_ *H]R!];9_[^B_WI?\_1%X,W\#?L/5Y?>F]M MF3?R;/CY20[NVQ+5TW<&WON*6+/8J2H@_P!^=V4G[T*U9DB]0MZ@.?>/&T3P M#W]O)BZ>%X#]U13_ ''C''AQQ]O0_NT?^HT*4.O6,4S_ &C>75&G]Y]M?\]# M@_\ S[4'_P!4>\A_K;/_ ']%_O2_Y^@!X,W\#?L/5JW\F[>VS,;\T,54Y'=V MV*"F_P!'F\XON*W/XJE@\KMB&6/RSU<XD][;FVEY#E2.1& M;ZB' 8$_$?0]"ODV.1=[4LI \-^(/IT4KYL;JVP_R\^3+IN/ NC][]LNCIF, M>RLK;]W RLK"H(964@@C@CV)O;B[M4Y$VI'EC#BT6H+ $9;RKT6\P12G>[DA M6(\4^1]!T5[^\^VO^>AP?_GVH/\ ZH]C7ZVS_P!_1?[TO^?HF\&;^!OV'K=^ M_E\=G]:4?PP^/%-5]A[&I:B#KC!Q34]3NW 03PRQPZ9(Y8I<@LDW.T6'^_@Q/*MO\ W&RD?Y7]&4@C^H/O)_E:>%>6[)6=01;IYCH&WJL;N0@' MXST%?]^MD_\ /8[5_P#0AQ'_ -5^S[ZBW_C3_>A_GZ2Z&]#U>#@NRNN?]EB^ M/Z?W_P!E:Z4X".J7^]6"U4TG^CS=T7CJ%^_O"_D4K9K'4"/K[Q_O64\YWK C M3K?/EQ7H41@_NZ,>=!TFO])O6_\ S\'9'_H5X'_ZO]F6M/4?MZ3T/0O=-]G] M:)N6(OV'L90)@26W;@% '\*S:WN<@.-3 ?ZY]D7,+*;%:$']4?\ '6Z5V@/B MG_2_Y1UIR?*?=NU:CY+_ " G@W-M^>&7N3LB2*:',XZ2*1&W=EBKQR)4LCHP M^A!(/O-?E"[M%Y5VU6EC#"Q@J"P_WTOSZA?=8I3NER0K4\=_(_Q'H!/[S[:_ MYZ'!_P#GVH/_ *H]B+ZVS_W]%_O2_P"?HO\ !F_@;]AZV!?Y@N_=BU?\KKX- MT-+O3:=36TU)U&*FCI]QX>:JIS'TYE8Y!/3QUC2Q&-R%;4!8FQ]XX^W$\*>[ MG,4CNHC:6\H20 :W@(H>!QGJ0.8$<\J[>H!+!8L4_P"%=:_7]Y]M?\]#@_\ MS[4'_P!4>\COK;/_ ']%_O2_Y^H_\&;^!OV'JY;^1UOG9.+^6>^:C)[PVMCH M'Z#W5"D]?N#$TD+2MOWK-EB62HJXT:1E1B%!N0#_ $]PA[^W%O+R;;+%(C-^ M\XS0,":>!<^AZ&?(TN;9)(Y$J2KHZD$$$@CW*/*MY:+RQMRM+&&%C!4:E_WTGSZ# M6YQ2G<;@A6IXS^1_B/0)?WGVU_ST.#_\^U!_]4>S[ZVS_P!_1?[TO^?I#X,W M\#?L/6Q)_I V'_SVVT?^X=S^#?\ 'R8;_B[_ /.J_P"!O_%R_P";'^=_VGWC M3X\/\:_]/+U<1\/\7^E^?#J1=#^A_P"5=IP\_3[?ET#O8O2W3F2Q>P,SD>IN MLZ_,9NF[FR69RM;L/:U5DLOD9/E=\AH),ADZZ?%255?6R0P1HTLK/(51038# MV'/;.UM9]AE>>.-V%VXJR@FGAQ8R.'0@WAW6Y4*2!X8X'YMT%_\ H+Z2_P"? M.]6?^B]VE_\ 6CW(O[NV_P#WQ#_O"_YNBGQ9?XF_:>K:_@G\:OCGENA>T*O* M= ]*9*JI]VUL<%3D.J]BUE1!&-N85PD,U1@9)(T#L392!"'F6R2 M)$5#&E0 #^JW$ ='^ULS6IZ>]M_&7XW/N#"(_P ?.D'5LK0!E;JC8;*P-5%<$' $$'VG MO((1:2D(M?#;R'H>KQLWB+D\1U13_.8Z0Z7VS\P8,;MSJ'J_;^./4^SJDT&$ MV!M3%41J)"27ZR45 M9%8THF*D$]1_SG<7$6\Z8Y'5?"7 8@>?H>JG?]&/6O\ S[W8_P#Z"> _^M_N M8/W)LO\ RB6O_.*/_H'H)_67G^_9/]Z;_/UM.?R2?CI\?-U?$_?-=N?HGIO< ME;!\@-V4D%9GNL-DYBJAI5Z[ZJF6FBJ,A@ZB:.G6:9W" A0SDVN3[Q$]]+:V MM.,V223P7UZN'_ -E-^+'_ M 'C1\?\ _P!$UUU_]CGN&>A=U[_93?BQ_P!XT?'_ /\ 1-==?_8Y[]U[KW^R MF_%C_O&CX_\ _HFNNO\ ['/?NO=>_P!E-^+'_>-'Q_\ _1-==?\ V.>_=>Z] M_LIOQ8_[QH^/_P#Z)KKK_P"QSW[KW7O]E-^+'_>-'Q__ /1-==?_ &.>_=>Z M]_LIOQ8_[QH^/_\ Z)KKK_['/?NO=4U_-WX===5?=KR[)^+&RJK"G:V'_56;UXG;#4GW/B6,-_:TA;\6]SER'-LBJZ#,+N_F]HTN26 MF'7])/#)&F4VY'5" 5\#.I T^9"1Z@?<,\T&REYQ_P 2,36I$?P:2OPBOPXX M\>C^S\1=O_4U!ZGC6O'Y]8O]EG^.'_>/W2/_ **G8G_UA]K? @_@3]@Z9UMZ MGI0[6^,_QP_CV%/^R_=)7_O'LY;_ .BG8E],V]=N02K_ ,6'],L$KHP_M(Q! MX)]E^ZPQ+M\K*J@Z?0>HZ>@9C*H)-*]:[G\U?ICI[ _,[L'&X+J?K7"XZ+'X M-HJ#$[%VOCJ*-F@F#-'2T>*A@1F"BY"B]A[R7]G]KVRYY!LYKFW@DF+S59HT M8FDK@5)!.!C[.HTYLN;B/?)4CD=4 3 8@?"/('JN3_1CUK_S[W8__H)X#_ZW M^Y._38XWD)9M;Y)J?B/KU:-_LIOQ8_[QH^/_\ MZ)KKK_['/<5]";KW^RF_%C_O&CX__P#HFNNO_L<]^Z]U[_93?BQ_WC1\?_\ MT3777_V.>_=>Z]_LIOQ8_P"\:/C_ /\ HFNNO_L<]^Z]U[_93?BQ_P!XT?'_ M /\ 1-==?_8Y[]U[KW^RF_%C_O&CX_\ _HFNNO\ ['/?NO=>_P!E-^+'_>-' MQ_\ _1-==?\ V.>_=>Z]_LIOQ8_[QH^/_P#Z)KKK_P"QSW[KW7O]E-^+'_>- M'Q__ /1-==?_ &.>_=>Z]_LIOQ8_[QH^/_\ Z)KKK_['/?NO=>_V4WXL?]XT M?'__ -$UUU_]CGOW7NO?[*;\6/\ O&CX_P#_ *)KKK_['/?NO=>_V4WXL?\ M>-'Q_P#_ $3777_V.>_=>Z]_LIOQ8_[QH^/_ /Z)KKK_ .QSW[KW7O\ 93?B MQ_WC1\?_ /T3777_ -CGOW7NO?[*;\6/^\:/C_\ ^B:ZZ_\ L<]^Z]U[_93? MBQ_WC1\?_P#T3777_P!CGOW7NO?[*;\6/^\:/C__ .B:ZZ_^QSW[KW7O]E-^ M+'_>-'Q__P#1-==?_8Y[]U[KW^RF_%C_ +QH^/\ _P"B:ZZ_^QSW[KW7O]E- M^+'_ 'C1\?\ _P!$UUU_]CGOW7NO?[*;\6/^\:/C_P#^B:ZZ_P#L<]^Z]U[_ M &4WXL?]XT?'_P#]$UUU_P#8Y[]U[KW^RF_%C_O&CX__ /HFNNO_ +'/?NO= M>_V4WXL?]XT?'_\ ]$UUU_\ 8Y[]U[KW^RF_%C_O&CX__P#HFNNO_L<]^Z]U M[_93?BQ_WC1\?_\ T3777_V.>_=>Z]_LIOQ8_P"\:/C_ /\ HFNNO_L<]^Z] MU[_93?BQ_P!XT?'_ /\ 1-==?_8Y[]U[KW^RF_%C_O&CX_\ _HFNNO\ ['/? MNO=>_P!E-^+'_>-'Q_\ _1-==?\ V.>_=>Z]_LIOQ8_[QH^/_P#Z)KKK_P"Q MSW[KW7O]E-^+'_>-'Q__ /1-==?_ &.>_=>Z]_LIOQ8_[QH^/_\ Z)KKK_[' M/?NO=>_V4WXL?]XT?'__ -$UUU_]CGOW7NJ!M[_\>SU;_P!JGN/_ ."R^1?N M>O:W_E7YO^>Q_P#JW%T&-Z_W*7_FF/\ "W0;^Y)Z*.K@O@)_V3]VM_X>%=_[ MS6#]PK[B?\K/8_\ --/^KK="':O]PI?M/_'1TI_:?K?3YMG_ (^+!?\ :VQ_ M_N5%[37G^XDO_--O\!ZO'_:+]HZH)_G9_P#99U/_ .(AV7_[N=W>\AO8C_E1 MO^HV7_ G4=<[?\EK_FRO^7JH;W,W00ZVR/Y%?_9(N_\ _P 6(W=_[[?J7WAQ M[^?\KO'_ -*^+_C\O4N]^Z] MU[W[KW7O?NO=>]^Z]TVYG+4>"Q60S&0D$5%C:6:KJ9"&.F.%"QX56:['@Z+9CODS@LYN#JO;U"64[ R<&*IC4S4M%(XDEIWJV\%//[KW1A-S8'^\6,DQWW7V>M:M?-X/N+?= M8ROQU_'YH+^/[[7^KG3;B]PHM9_IKA)Z:M)K2M*_GGJDB:T*<*] I_H _P"S MM_\ 6#_^6?8A_K+_ ,)_XW_T+TD^B_I?R_V>G#%]'_PROHJW^\_G^SR6$R/B M_@OC\G\'SN,S7AU_Q:31]Q_#O%JL=&O59K:2FN]]^JMWM_"TZA2NJM,UX:1_ MAZO':Z'#ZJT^7^SUJ>_S;?\ LMOL7_M6X'_K34>\PO9C_IWMG_IYO^KS]1'S M?_R7IOL3_C@ZK2]RET&>MPW^3-_V1;C/_$A[K_\ =?MWWA)[V_\ 3PKK_FC! M_P!64ZF3DW_D@Q_Z=_\ CYZM>]Q-T*>O>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)=\(LKC\5\8MH/7U M^/H6K>R^^,;CAD:V&A2ORM9\A>U5H<;323&\U962+ICCC5Y'/Z58\>_=>ZD; M>^9VQ\AL7"=C[AP]9MW:U=L[&Y?-3Q5-7FJ[![QJ/CE!\JZ&:AWTN\]J=CT-7CEPVY=B96;:&\<-#6OE* M3%YRHVKMK>U%!1YAJ'&QY6"HVKO+&U#21PJLO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MDON79.SMY?PQMV;4VUN:3!U4U?@Y=PX'$9R3"9"HI)J";(8@Y:CK!CZV2BJ) M(FDB"LT3LANK$'W7N@7VW\4NG=K1[-CQV(R;)L7)9+*8*.7+30TD=1E.PU[8 MGC;&XY*'%T]+'V-!3Y5(J:"G02TL4)!IM<#^Z]T9#W[KW15L_L%\WVMMSLO= M75N$QN]-DX7L";%[PV"L&[=PY; 3P':^W,!+N[.;5V9D<;DZN@W%4Y,XB/S4 MU-54PT5-2+O[]U[I]^,VULULW9>Y\#EMN;>PE+3]B[GFV_E\'LK_ $?Y#?V% MJHL9.V_MZ;=DJ):O^_.=S3UB9"MJ$IY/11=;%M-[.;FZA5YVI4DMY"@X M$#AT#53\&OY9M)B=V9N7I+ OCMC[EJMG[G:EJ.WJZJQ^Y**EH:ZIQ<6-HLO4 M9+)R1T>2@EUTD,\3(]PQ"M8R_P!=?W"_Z.#HSK/J'JSKG"X+HW X_;W7.6CBW7A:;%UF5KJ&LBS]%1U$.4@J,S65U=SW^^;<]WE,]\X4%R%!(4!5PH P !PZ-K2SMK& 6UH MH2$$D 5/$U/$D\>A?]EG2GKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB7_"#$XO+?&39JY/'T=?]AV9W MWD:!JJGBFDQ^1A^0';,,&1H)74R4.0@BJ'6.>(I+&'.EA<^_=>Z&3!_';I_; MF$V_MO$[4J(\%MC;^"VOB,96;IWAE:88;;E!1X7&0Y(9;<%Z]T)6V-J8+9^.?&8"DFIZ>:JDKJN>MR.3S65R-;+ M'% U9ELWFZS(YG+U:4M-% DE342O'3010H5BBC1?=>Z!OLCOVGV3E\CADK9 MZ!()6DI& 'OW7NGK:_<"[BW-U5MM:#;M='V?TYNKMNEW+L_=TFZ=JI3[8RW5 MF,6CP&4FVY@9=RX;-0]GQ5-)DC#1%XJ;FF'E!3W7NJ\OFS_*J_V<7N>/MW_3 MQ_HZ\>T,+M3^[W^B_P#O=?\ @];EZS[_ /BW^D3;%ON/XKI\7VWH\=];:K"9 M^1/=W^I.Q?N7]W_4_K/)K\?P_B"BFGP9.&GCJS7AT$-[Y4_?%[]9]1X?8%IH MU<*YKK7U].BA_P#0/_\ ^!:?^P'_ /TS>QG_ ,$9_P!(;_L[_P"W;HH_UO\ M_E[_ .J7_73JV3X*_$'_ &2OJ+/]5_Z0_P#27_'.Q,OO[^/?W3_N;]K_ !7; M>TMO?PG^%_WFW5Y_!_=;S>?[A-7GT>,:-3PWS]SC_7C>UWGZ;Z73;I%H\3Q/ MA9VU:M$?'52FG%..>A=L>T_N:R-IXGB5O1T?8)Z..O>_=>Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H#^[ M^GJ[MW9N\-L4&]LCM>HW5M;^ZR&LH9=P[6QT4N6H;";? MS6V]O8*HVK#%@NXMDUE5D3/M\2MDUJJ9'@F:#[,']T^Z]T9+;>,GPNW<#AJJ M7&SU6)PN+QE3/AL0FW\/-/04,%+-+BL"E7D$PF-DDB)@HQ/.*:(K&)'TZC[K MW3U[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO MW7NO>_=>Z][]U[KWOW7NB?\ P0_[)FVO_P") [__ /@A>T_?NO=' ]^Z]U[W M[KW017]U[INVQTEUQL_,[6W!@,3EJ3*[+VQF]G; MXNKGFGIY)WR$4]9K%565DM1[K MW2JW7-N-(:6##XG&Y#$529*'<]9-N'-8C.XG&_PRJ:"JVOC,+MG-2[BRTM:( MXQ3M68LHC&1)F=5B;W7NB=]*=-XREQ/76Y-^=3B7>\/Q:ZNZN[*K,CM/%U&; MWUE]WX[;6VMYXW?&8R21UV?38<77<25"22U"BARZ]T9+H;8^+Z] MZIVMM_$;?I]ITM2N5W2^UJ3$4F!I]LU>]\WDMXUFV8,30PT]/0TVVJG.MCX8 MPBE(:9%(!%O?NO="_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ MHG_P0_[)FVO_ .) [_\ _@A>T_?NO=' ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$"^,NX MZO9WP7S^[L?)X:_:TGRNW%13:]MQ^*KPG2II->\MR;-VBFB:F4WRN8Q6 M.'_*364T.N9/=>Z4WQ9^4F>^0.;W'25."VY4[5I\1#GMK[YV2F]2SE1CZ.O[]U[HJ&\NUN MW\1WEO;9FRL5U'N':.T^F>OM_P"9INP]_P"[.L:O;=5N'=7:^,K,W)N3#=3= ME82LPM=CMEHIAJI*.6G:CDE74AD(]U[H>>M-WQ]@]<; W[%4;9JXM[[)VKN^ M.JV5N>#>NS:F/5+24%+NW;,RUNJ@R<<$$=?2F.=8T$@4>Z]TY M;QRSX':6Y\W'74>+?$8#+Y-,ED*2IKZ''M0T$]2M;64-&\=764M,8][6PFQJ[LCJ//05,>5BR&(VGMWK&AS9RU)M:;< MB8RGJ]E_-KY"9&3[/'20U4]3%@Y<25U4YR,=6K4_OW7NK)/?NO=$[^1_Z]T8#J?,;KS^P,#EM[QR1[HJCEAE$EV77]=O M_D^"BK)HB%DAI:B M6-BJ.%>.)W0E))Z:-P&'T:2-3^64LX4 MR%+O:&BVE45_8FZ)9-C9:KP>Y][X_)]A8G"]![8S&Y*99\&=L2]PX[_=>Z!;Y!]E/U!U3N/L@UM)CJ+:;XO)Y>OR5? MU_B<71X5,G21Y6HRV6[0[#ZIV3B\9'12.9ZBLS^.\4=VC7Q];"E3#%)F=Z]?[?;>$WOWPE%1=$9#KSJF7;TU=E. MR>V-T]/U6SZ&NV__ !2KJ\YDXNG=^;4R&*K7#/#.V3I7@\;+.B!D8^Z]T;;; M66_C^W,!G;T)_C6$Q66OC*^+*XT_Q*A@K+X_)P!8^JSK+IKLC?^/S6"V[6[2VKDLU2YS77E%5T M$9/[B39W$Q6Y:JA6[CW7NBS_ !2^4>6[WWQN? U>_P#K+=V/Q&V),M14VQ\# ML7$UYEIMP1X2MR%2VT/E;\BJQ<=3U:R4RK74>&\T@\M.]1"0Q]U[H^GOW7NB M'=S]Z]SX?M_<'7G4%=@LS%MG:N&S6ZL13=!9SM[<.TI,_B]P56WJVMFV[\C^ MLZEX=R5N',5-2RXJ'B)V6HD!/C]U[HZ>UJO)5^V-N5V95TS%;@<15Y9),5-@ M9%R51CZ>:N5\'49#+3X9UJG<&D>KJGIS^V99"I<^Z]TD^XMSY;9?5^]]V8)F M&8V_@*O*8]8\9BLU-+44NAUIZ?$9S=^P<3DJFI ,<4,^:QJ22,!YT)'OW7NB M]] =I_(7M3<^.W)OW ;1V=US7;=RD=/M/9^'S&?R^(W305D$?V_9V]]YYG9& MYMG;L./DUS;3@V)-2X^9O1N;*1%&?W7NCG>_=>Z][]U[KWOW7NHE>U0M!6M2 M:ONEI*EJ;1&DK_<"%S#HBD9(Y&\EK*S!2>"0/?NO=5]="?,K<7;/:-+LBGP^ MVMR[6;^+8G*;AVNQ7R H^NNN\7UCN;#CIQM]9K [\W=NO8 M%905"[PJL+'G:/=&WNL.RZ&2A:GA,,E+51TI+J'C=K.![KW0O]/;^':76.R^ MP14;(J_[U86'*-4=;;XI^RMB2N\LL4AVOOREQ6#@W3B5DB(2K6CIO(0;QJ01 M[]U[KAW-O&IZ_P"K]Y[RH\MB,'5;?Q)KJ?*Y['IE,/23?Q ML!L#'Y 9&AKXZ"N,TVQ_EQ\D:Q**@GO'Y*W'XFBJG-Z.LK+.J>Z]T?\ ]^Z] MU7]VEWSWE2=Q]A;"ZFK,+G<1L:AQ:[AHL?\ '7<':N=V=E\QLW#[DP=#D\K@ M/DQL'[V?Y\1CH M=K4>$3/5>Y(Z^#((,5#21;BPF;I8GJ4CEJ*O%4N?RM)2Q2RTV'R3K]NWNO=- MGQ]W;W9O23[9CV72XG+4FW,ML.@ZUQ\V4V)18?)4#U%7!C>U,ON8;G[2K M8ZLE9:^MV?L+QH$1<5?5/)[KW1E??NO=>]^Z]U[W[KW08=S[SJ.N^K]X[[@J M(Z1=HXR//UM7-4;/I*6EQ.,K:6IS5375N_\ >/7NS:#'4^(CG>IJ,AF\73P0 M!Y#41E0??NO= +\7ODMN3O;);HI,OM_;_P#!L?34.4VYN[9E/O\ K\%D<=D( MH*FGI,EN6IVE6=,Y+)RT57#4POM'?6\*2>"77Y$C$/R! M[>VANCY1UN/H>@G=^;/FP\ MD^6:K-=+D:5J*":TZJ@C8^Z]T=VEF%134]0#$1/!%,#!*)X2)8U>\,P"B:(Z MO2P U#GW[KW0+_(WL6OZGZ>W/OS%Y_;>V*_#U^S:6GS6[\=B\IMVE;<&^=M[ M;>'(TF;['ZCP_P#E\>7--%+5;DQ5/3SRI+)*RH8W]U[H%/B)\DLC\@:W?9J] M\]=[RH,#A]D9;#G8N"V=A)8J#=$V[!%E,I#M/Y,?(N:"++)A%$%-DC@LA3FG ME\E,VL%/=>Z.U[]U[JOOM9V5O';G6E7A]Q;4VEG=R;>SLV'^..X>P23!TK4T:0F2GD$BL_NO=6!J254GZ ME03Q;FW/%S;W[KW1=_DQVEO3J+8V%W3L/;S[NSL^\RVQ*?KO%"78,&U\OAUKT&W>Q:S>6:SO; :HF.O-5FW]DF:(0Z,)3 M@M)+[KW1A_?NO=% ZLV'O[I?XD[IVK7383%;]PE#\A=Q8NJEWI0;4P=%5[GW MYV3O?:E97;^K=K;TQNTJ6*ASE))4Y*?"Y>+&>N62BJA$89/=>Z17Q@V?N/$] ME;BW;OCL/I_?&\-U[4R,U?0=39'J^'$;9\>9V[)4I!0;Z]T(>?I*JOP>8HJ)=5968NOIJ5?XM7X'543TLL4(_C MF+@JLGA[R,/\IIXI)H/UHK, /?NO=%:Z3Z?[BV?N3'[F[,W+1;BJVQS8N;"8 M7M'LO)=<[+H8Z*JCIUV#L+>&*R.0J\S4NE+!5Y3-YZOG\2U#44=!%4/1^_=> MZ-W[]U[JO/YBFCQ?:'4.X\IUWD.Q<>FRNQMMKCVD[[I\%19/<.[.IX\8U34] M$?&CO3(?QG(U=,L-)'7Y+#QR6<14]:?(]+[KW1@?B?C*W#]#;-HZ M,'5PFHI*JG4J&GIYH5+&15!EC9 6:)DE"W;DJ0W]"#[]U[JNOHOXQ=J=?]J; M(WUN?(;A?%[?BJ]IC;([_P"X-];8I-O8C9NZ,72[YR^,WSN?()F-S9C<&;2C MP."6G?%[;V^U143U%5EIXS1^Z]U8Y[]U[KWOW7NO>_=>Z![OC(;NQ?6.?KMB M9#;6,W=#+B_X%4;RWU1=<;2:N?)4L:4^Y-V5VPNS4H<-4*Q2>./"5T]2A,,8 M1W$B^Z]T!OQ4V37;0RN\*G.[\ZU[(W-N2*+)Y;,];OU?A<'A##+!2Q87$;/V M#UKL_.4V)JD43FJS^8W/7_<(RI510LD">Z]T=/W[KW5'/S1V=BNX-KMA-VT-+7)\@-K5W4TLE!_#JK8" M265P']3L;D^Z]TR]MX'=T8" MNR4,58)JA*[-5TBZ4_R&)3^][KW5D'4M'48_JKK.@JTGCJZ'K[9E'4QU,=;% M41U%-MS&PS)419+";:R,F@:\2^Z]UD[1VO5[UZ]W?M2@9 M$K<[A*N@I7>NRV+,<\@#120Y+!Y#%9;'U4;J&AG@J(GBE"M>P(/NO=%5^.GQ M_P"Q>MM^U>\-YY#<=:NXL9DJNHV_D^[.R^S=K;$JY9::BQ])@9=^9S(9+=F^ M,[CZ.I3(Z4^/@BAB8S>Z]T>?W[KW7O?NO=>]^Z]U$R!04%:9)98 M$%)4EYH)HJ>>%!"Y:6&HJ'C@@EC'*N[*BD7) !]^Z]U6_P!3;7W]F.Y=M]C= MJ=D]&9_+1Y"KQ."V'U[O;JG/9>CQ[K7?8YGV[^NL+E5Q&^*F;;\]3CNG>J^T(\'D.Z]P!O'=:V9;- M[]U[H3NR\)F]Q[$W-A=M18^;<-;CBN#3+[@W)M;%+EH9H:G'RY+.[/1MST5# M!50J\HHBD\T:F(21ZS(ONO= WTEU9VCLG-UV>[(W.V\)ZUV-N3"HNV,%/*)'GGR&6S69FLB2UDJ*JI[KW1G??NO=4^_*"B6+ MMGY!8H=5YS=V9W]M?#IMS1_ATU3$]2* MK/9EEFDM+'2W$"^Z]U;-M>&2GVUMV"76)8,%B89 ZRHXDCH*='UK-2T,ROJ4 MW#P0L#]40^D>Z]T%GR!V-N'?VPDQNU::6MSN*SV+W!04=)V#N_JJOK9<]^Z]U[W[KW0;=O5VX,9UMNO(;4K,50[FHZ"&HP%1GMYT M77F".7CKJ1J"FSF] M_=>ZH=^?FS,/N/O'>N3&5PVX<_MK T.;I M),I%\A=KU/1:ML3'TC[XQ>XJWY@_&OXZ[AK-O4T+YI?X9646XZ6"JJ8(XGFE M>2J]U[J]?'_\ *+]SS?Y)3?O DB7]E/W 6FJ&/D^O,CGG]3?4^Z]T&_=.W-Y M[LZVSV"Z]. CWG556VZC!3[HW%O?:^ HZG&;IPF5FR&2RG7-5C]Y30XZDHI) MQ04E51C*O&M%/4TU/42SQ^Z]TD>B^M=\]>GX=J0=69[.;AW=N#>&6V]O!U^4+56*I4JJ&*MDP%#L;X4;ZZOKL M)!65\9J&J-Q972U:P:NHR4CI/=>ZN*CN(XP?J$6_U^ND?U /^\#W[KW0%_(; M8FZ-^[(Q]'LZFDK=P8+<^/W'0T-/V5OCJ"KKVIN;^&25(BII*DP:?=>Z2?Q>Z9W3TM@]Q;?W3GL]NR=Y=OPT>Y=Q;QW M5N66JCHL.KU^)VKA]S[FW?4;,ZTP.7KJB# 8^7(5.22DU&NEGG_RF;W7NC1^ M_=>Z#KN"FEK>I>T*."/(33U?7>]::&'$T&+RN4EEGVWDHHX\;B\WMK>>&R5> M[L!#3U>'RM+-(0DM'4H6A?W7NJSOAKG<[2=AU=/L[-+NS<]/V]GMI?'3X[;MQ6[D-!/1XO$T$V;J:VOG!JL)BZ* ME>OI_=>ZMV]^Z]U7)\N^VNU>N^T=GX_9&0^1[X#)X+%-F\7T1UQA>TX*9JBH MWM1QUF;H*3XN=_9_9=769,8_1D,G68W$UE'25*TZ-+2U4@]U[HW'0W8.&[$Z MSVU7X[=D>\LO@L/MW;F^,K_%,#G*R+?5/M/;V5W#09C,[3Q."VED<]3R9>,U MSXNCI:%*MY(XX*?0T$7NO=#'[]U[KWOW7NO>_=>ZK^^9NT*+=&Z^L4KUR4L# MX+<>,DEP'5_IMO8[;]3F*[;M#6;CI<'7[EVUN'9NZ:RCB MW)E143;HVKNC#X'+8//)E#41SH:2FAF*">&&GBE2FA]U[H;??NO=>]^Z]U[W M[KW7O?NO=>]^Z]T OR92H/2^[YZ65J:HH8J#(Q5K1;?:@Q[4&1IJK^(9RHW- MUMW!B\9M^B$7EKJP[9S4M)3*\L=,[J+>Z]T2WX*YC-QYJEBDQU#2[KH:"G5Y:NJQ M3O34U3[KW5IGOW7NJN_DEW/V_LCNE-M[8S/R;3;E4XJ*].I^M]L[_P!E8FA? M"2_;2Y7=47Q,[AAZ]F;*H):G^\&X*2,4J-+$D:&Y]U[JP+JO?&W>Q-A[>W1M M?]^Z]U[W[KW57OREV)M[6W-UK MTMWAV7O_ &;M_$X3<<%;A,%)LWJ3L;K<3[VJZE4JI:^6.OIL='*L$)DDCFC] MU[JPSK9='7VRD4QM3IMC"I0M'0Y;%ZL6M! N):;&9Y4S6-JVQHB,]/5 3PS: MD?E3[]U[I;>_=>Z][]U[KWOW7NO>_=>Z][]U[J%DH348ZOIPDDAGHJJ$)"M, M\KF6"1 D25C)2/(VJRB4B,G]1TW]^Z]U2KU5FLYA._,K)M7.[-[EW92[@I%R M/2?6>]OC?7=U;!:BADP..S'<^RO<3VQD#1?Q"KBFK925]U[HPWQL[*Q_8?6F%B?=U7NW>>V<=BL;V%)E\CM MG*[EQ.YJV@CR;XO=M7LO;&S=IQ;GAI*B,UE+1XO'_:2'Q24T,BL@]U[HP/OW M7NO>_=>Z][]U[JJ3Y'[!VUG.\-\5^[*S=V/PAI(,OEMT===$=^]E;NP])3=? M;;QV*V@,CMKJK>'6*[=R]725M;FWBKH,R]*:6"&:B='F;W7NK/\ ;)F.W<%Y MU@27^$8[6M**M*?BDB ,4>0BAKHD9;$),HE3]+7()]^Z]T^>_=>Z][]U[KWO MW7NO>_=>Z][]U[H)N]():CJ/?24Z5KSQX;[J#^'T6'R$R34=735<4TM-G=F] MBXT8^"2 /5RM@,W)!2K)+#0U4R1P/[KW5=_PJS6GK0D5%*A;W7NK(]B[VVMV M%MJCW/LW<..W5@9ZC)8V+.XFJAK\;6UV"R55A,O]ID*5$HLA%3Y7'S1B>GU4 M\VC7$S(5)]U[I7^_=>Z][]U[KWOW7NJG>XMA;9K.Y=W5&Y*O=N.I=O9#>N=K M=R[)Z$^0._*FMR>XJ#8&X-G[0W+G<3U=F^NJ#KS'4?\ $IMQ-BZ]U:Y3&5J> SI'%,88C-'#(\T,/ M?NO=9O?NO=>]^Z]U[W[KW0/?(;_F0/>/_,OO^90=E?\ ,VO^95_\>9FO^9E_ M]F!_SN/^K=YO?NO=5X_ ?_F:^=_[=X?\>?VE_P!DE?\ ,SO^9J[9_P"/C_[] MA_SJO^F?[#W[KW5M_OW7NJC/GY_IL_TO;&_T;_P_^ ?W8P/\2_NU_P .1?WU M_B?\;WAX/[X?\-__ .0_W,\_VG\/_OO_ )%?^+?:>G[WW[KW5B_0=_\ 0GU3 MYO[D?Q'^X.V/X]_HV\G]PO[T_P )IO[V?W4\_P#E?\&_O+]WXON/\JM_G_WM M?OW7NA<]^Z]U[W[KW7O?NO=$>^77\<_C.P-'^G#_ $>?P;=7^F+_ $.?Z0/O M?]'/\>#[G[#_ '^G]U/XY_=K_?CU_>#_ $0; M2_O/Y/XQKW'KU?QW[;[#^]><_@O\(_O-_OX/[N_P7[?^&?>?O_P[PZN??NO= M#1[]U[KWOW7NO>_=>Z][]U[KWOW7NBS_ "[_ .9%[D_YD7_Q==J_]E*?\R5_ MX^/&_P#'\?\ 3!_J/^;VCW[KW14?Y>?_ /WI_V11_P"R/\ V21_Q=?^/MKO M^9D_],O_ #S_ /U;??NO=6C>_=>ZI7^8W^G;_9AU_N?_ '>_NQX*75_#O^'- M_MOM/X5)K_TJ_P"R=?\ ./7V?W6KQ_WV_=^P\GE_8T^_=>ZMYZ_^V_N)LW[/ M^[GV_P#=?!>/^Z'V7]U?^+93:_[N?PW_ ''_ ,$\E_MO#^UX=.GBWOW7NE?[ M]U[KWOW7NO>_=>ZK>^4_]Y?])5;Y_P#35_HS_NA0?>_W:_TJ_P!Q?]+>C)_Z M*_[R_P!R_P#+/]&G\3O_ !G^ _N?Q;['^/?[B+^_=>Z/EU]_%_[A;(_O!]W_ M ![^Z&VOXW]_]Y]]_%_X-1?Q+[S^(?Y?]W][K\GG_>UWU^J_OW7NE?[]U[KW MOW7NO>_=>Z][]U[KWOW7NF?<7_'OYW_-_P#%FR?^=_S7_ *?_.?\V_Z_X>_= M>ZI.^-W_ &4C@_\ MUS_ ,?7C_\ F1G_ #.+_CWLE_QXG_3=_P ]#_TT^7W[ MKW5Y/OW7NJIOYB'^E[^]77'^CC['^%?PW_?P?W8_X<(_TG?\7>;Q>3_AO+_? M\?W.M;Q_WE_W"_=^7Q?N^3W[KW1UOBM]_P#Z >M/XW_<'^\_\ B_O=_HS_CW M]T/[U>67^.?8_P![/]_?]U]Y?[K^,?[E?N=?W?[^OW[KW1@_?NO=>]^Z]U[W M[KW58/R8_OO_ *4=Y>'_ $W?W2_AN-_N5_!?]+O^CW_3C_=;'_W>_C']U/\ M+O[L_P #\G\(_@G^_>_O=]Q_>'_*OX9[]U[JRO"?_OW7NG/W[KW7O?NO=>]^Z]U[W[KW7O?NO= 3\F M?^9&[_\ ^96?\ L5_P SN_YE+_Q\.(_X_P#_ .S;_P"._P#A;W[KW1#_ (!_ M\S"W=_V0+_Q;]X?]DB_\?C_Q^@_X^W_LP?\ GG?^F;W[KW5LWOW7NJ2/F_\ M[,#_ *>L]_H__N9_=O\ @L'\,T?\.6?P#^-?W-Q&C_3Y_LHO_.-O\+\GW'W/ M]_\ ]W^ _9?<_P"X_P 'OW7NKG-M?PO^[N"_@G\)_@_\(QW\+_@/V_\ _L/ MM(?M/X/]I_DW\,\.GP>/T>.UN/?NO=/?OW7NO>_=>Z][]U[JK_N7^_7^ES=N MK_3?]C_%)/\ 0]]M_IA_N-_I$\.SO[T_Q+^ ?[BOX_\ W/T?Z/?!_OQON/XK K_&/]RWWWOW7NK/DOH6][Z5O?ZWL+WM^;^_=>ZY>_=>Z][]U[KWOW7NO_V0$! end GRAPHIC 12 j2280752_ba008.jpg GRAPHIC begin 644 j2280752_ba008.jpg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end